Bionik Laboratories (BNKL) 10-K 29 Jun 17 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2017	Jun. 25, 2017	Sep. 30, 2016
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Entity Registrant Name	Bionik Laboratories Corp.
Entity Central Index Key	1,508,381
Current Fiscal Year End Date	--03-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 31,056,046
Trading Symbol	BNKL
Entity Common Stock, Shares Outstanding		48,885,107

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Current
Cash and cash equivalents	$ 543,650	$ 5,381,757
Trade Accounts receivable	383,903	0
Inventory (Note 5)	228,249	0
Prepaid expenses and other receivables (Note 4)	228,047	231,733
Due from related parties (Note 8)	18,731	41,445
Short term advances	0	125,153
Loans receivable	0	379,908
Total Current Assets	1,402,580	6,159,996
Equipment (Note 6)	227,421	76,750
Technology and other Assets (Note 3)	5,030,624	0
Goodwill (Note 3)	22,308,275	0
Total Assets	28,968,900	6,236,746
Current
Accounts payable (Note 8)	784,726	320,871
Accrued liabilities (Note 8)	1,228,657	515,979
Customer advances	121,562	0
Demand Loans (Note 7)	330,600	0
Promissory Note Payable (Note 7)	236,548	0
Convertible Loans (Note 7)	2,017,488	0
Deferred Revenue	98,624	0
Warrant derivative liability (Note 11)	959,600	5,135,990
Total Current Liabilities	5,777,805	5,972,840
Shareholders’ Equity
Common Shares, par value $0.001; Authorized - 150,000,000 Exchangeable Shares; Authorized - Unlimited, Common shares Issued and outstanding - 48,885,107, March 31, 2016 -22,591,292 Exchangeable Shares Issued and Outstanding - 47,909,336, March 31, 2016 -50,000,000 (Note 9)	96,794	72,591
Additional paid-in capital	38,640,706	11,801,146
Deficit	(15,588,554)	(11,651,980)
Accumulated other comprehensive income	42,149	42,149
Total Shareholders’ Equity	23,191,095	263,906
Total Liabilities and Shareholders’ Equity	28,968,900	6,236,746
Special Voting Preferred Stock [Member]
Shareholders’ Equity
Preferred Stock	$ 0	$ 0

Consolidated Balance Sheets _Pa

Consolidated Balance Sheets [Parenthetical] - $ / shares	Mar. 31, 2017	Mar. 31, 2016
Common Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, Shares Authorized	150,000,000	150,000,000
Common Stock, Shares, Issued	48,885,107	22,591,292
Common Stock, Shares, Outstanding	48,885,107	22,591,292
Common Stock, Other Shares, Issued	47,909,336	50,000,000
Common Stock, Other Shares, Outstanding	47,909,336	50,000,000
Special Voting Preferred Stock [Member]
Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	1	1
Preferred Stock, Shares Issued	1	1
Preferred Stock, Shares Outstanding	1	1

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Sales	$ 571,945	$ 0
Cost of Sales	388,756	0
Gross Margin	183,189	0
Operating expenses
Sales and marketing	1,188,207	0
Research and development	2,663,146	1,397,554
General and administrative	3,346,230	3,676,125
Share-based compensation expense (Notes 8(v) and 9)	1,001,950	1,495,837
Amortization of technology and other assets (Note 3)	550,080	0
Depreciation (Note 6)	79,868	63,454
Total operating expenses	8,829,481	6,632,970
Other expenses (income)
Interest expense	43,735	2,839
Other income	(692,198)	(42,173)
Foreign exchange loss	115,135	112,771
Change in fair value of warrant derivative liability (Note 10)	(4,176,390)	(7,742,555)
Total other expenses (income)	(4,709,718)	(7,669,118)
Net (loss) income and comprehensive (loss) income for the year	$ (3,936,574)	$ 1,036,148
Income (loss) per share - basic	$ (0.04)	$ 0.01
Income (loss) per share - diluted	$ (0.04)	$ (0.08)
Weighted average number of shares outstanding - basic	91,784,976	71,554,822
Weighted average number of shares outstanding - diluted	91,784,976	79,984,257

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders’ Equity (Deficiency) - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Deficit [Member]	Accumulated Other Comprehensive Income [Member]
Opening Balance at Mar. 31, 2015	$ (2,498,745)	$ 0	$ 65,840	$ 10,081,394	$ (12,688,128)	$ 42,149
Opening Balance (in shares) at Mar. 31, 2015		1	65,839,563
Shares issued on private placement	0	$ 0	$ 6,568	(6,568)	0	0
Shares issued on private placement (in shares)		0	6,568,750
Shares to be issued for services	169,700	$ 0	$ 117	169,583	0	0
Shares to be issued for services (in shares)		0	117,471
Cashless exercise of warrants	60,966	$ 0	$ 46	60,920	0	0
Cashless exercise of warrants (in shares)		0	45,508
Share compensation expense	1,495,837	$ 0	$ 20	1,495,817	0	0
Share compensation expense (in shares)		0	20,000
Net income (loss) for the year	1,036,148	$ 0	$ 0	0	1,036,148	0
Foreign currency translation	0	0	0	0	0	0
Closing Balance at Mar. 31, 2016	263,906	$ 0	$ 72,591	11,801,146	(11,651,980)	42,149
Closing Balance (in shares) at Mar. 31, 2016		1	72,591,292
Shares issued to acquire IMT	23,177,000	$ 0	$ 23,650	23,153,350	0	0
Shares issued to acquire IMT (in shares)		0	23,650,000
Stock compensation acquired	2,582,890	$ 0	$ 0	2,582,890	0	0
Options exercised	18,166	$ 0	$ 110	18,056	0	0
Options exercised (in shares)		0	110,096
Cashless exercise of warrants	43,562	$ 0	$ 51	43,511	0	0
Cashless exercise of warrants (in shares)		0	51,249
Warrant exercised	40,195	$ 0	$ 175	40,020	0	0
Warrant exercised (in shares)		0	174,759
Share compensation expense	1,001,950	$ 0	$ 217	1,001,733	0	0
Share compensation expense (in shares)		0	217,047
Net income (loss) for the year	(3,936,574)	$ 0	$ 0	0	(3,936,574)	0
Closing Balance at Mar. 31, 2017	$ 23,191,095	$ 0	$ 96,794	$ 38,640,706	$ (15,588,554)	$ 42,149
Closing Balance (in shares) at Mar. 31, 2017		1	96,794,443

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating activities
Net (loss) income for the year	$ (3,936,574)	$ 1,036,148
Adjustment for items not affecting cash:
Depreciation	79,868	63,454
Amortization of intangible assets	550,080	0
Interest expense	41,934	7,697
Share-based compensation expense	844,162	1,495,837
Shares issued for services	157,788	169,700
Change in fair value of warrant derivative liability	(4,176,390)	(7,742,555)
Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities	(6,439,132)	(4,969,719)
Changes in non-cash working capital items:
Accounts receivable	(377,413)	0
Prepaid expenses and other receivables	20,525	(73,314)
Due from related parties	22,714	35
Inventory	(39,370)	0
Accounts payable	(332,010)	112,129
Accrued liabilities	18,674	183,033
Customer advances	35,075	0
Deferred Revenue	98,624	0
Net cash used in operating activities	(6,992,313)	(4,747,836)
Investing activities
Acquisition of equipment	(170,790)	(42,863)
Advances	0	(125,153)
Provision of a loan receivable	0	(379,908)
Net cash used in investing activities	(170,790)	(547,924)
Financing activities
Proceeds from issuance of shares, net of issue costs	0	4,552,409
Cash received on acquisition	266,635	0
Exercise of warrants	40,195	0
Proceeds from convertible loans	2,000,000	0
Proceeds from the exercise of options	18,166	0
Net cash provided by financing activities	2,324,996	4,552,409
Net increase in cash and cash equivalents for the year	(4,838,107)	(743,351)
Cash and cash equivalents, beginning of year	5,381,757	6,125,108
Cash and cash equivalents, end of year	543,650	$ 5,381,757
Assets acquired and liabilities assumed:
Current assets, including cash of $266,635	478,843
Equipment	59,749
Intangible assets	5,580,704
Goodwill	22,308,275
Accounts payable	(241,299)
Accrued liabilities	(361,029)
Customer deposits	(86,487)
Demand notes payable	(324,894)
Promissory Notes payable	(217,808)
Bionik advance	(1,436,164)
Non-cash consideration	$ 25,759,890

Statements of Cash Flows _Paren

Statements of Cash Flows [Parenthetical] - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash Acquired from Acquisition	$ 266,635	$ 0

NATURE OF OPERATIONS AND GOING

NATURE OF OPERATIONS AND GOING CONCERN	12 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	1. NATURE OF OPERATIONS AND GOING CONCERN The Company and its Operations Bionik Laboratories Corp. (formerly Drywave Technologies Inc., the “Company” or “Bionik”) was incorporated on January 8, 2010 in the State of Colorado as Strategic Dental Management Corp. On July 16, 2013, the Company changed its name to Drywave Technologies Inc. (“Drywave”) and its state of incorporation from Colorado to Delaware. Effective February 13, 2015, the Company changed its name to Bionik Laboratories Corp. and reduced the authorized number of shares of common stock from 200,000,000 150,000,000 1-for-0.831105 On February 26, 2015, the Company entered into a Share Exchange Agreement and related transactions whereby it acquired Bionik Laboratories Inc., a Canadian Corporation (“Bionik Canada”) and Bionik Canada issued 50,000,000 3.14 100 As a result of the shareholders of Bionik Canada having a controlling interest in the Company subsequent to the Merger, for accounting purposes the Merger does not constitute a business combination. The transaction has been accounted for as a recapitalization of the Company with Bionik Canada being the accounting acquirer even though the legal acquirer is Bionik, accordingly, the historic financial statements of Bionik Canada are presented as the comparative balances for the period prior to the Merger. References to the Company refer to the Company and its wholly owned subsidiaries, Bionik Acquisition Inc., Bionik, Inc. (the former IMT) and Bionik Canada. References to Drywave relate to the Company prior to the Merger. On April 21, 2016, the Company acquired all of the outstanding shares and, accordingly, all assets and liabilities of Interactive Motion Technologies, Inc. (IMT), a Boston, Massachusetts-based global pioneer and leader in providing effective robotic products for neurorehabilitation, pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) dated March 1, 2016, with IMT, Hermano Igo Krebs, and Bionik Mergerco Inc., a Massachusetts corporation and our wholly owned subsidiary (Bionik Mergerco). The merger agreement provided for the merger of Bionik Mergerco with and into IMT, with IMT surviving the merger as the Company’s wholly owned subsidiary. In return for acquiring IMT, IMT shareholders received an aggregate of 23,650,000 The Company is a global pioneering robotics company focused on providing rehabilitation solutions to individuals with neurological disorders, specializing in designing, developing and commercializing cost-effective physical rehabilitation technologies, prosthetics, and assisted robotic products. The Company strives to innovate and build devices that can rehabilitate and improve an individual’s health, comfort, accessibility and quality of life through the use of advanced algorithms and sensing technologies that anticipate a user’s every move. The consolidated financial statements consolidate the Company and its wholly owned subsidiaries Bionik Canada, Bionik Acquisition Inc. and Bionik, Inc. (the former IMT) since its acquisition on April 21, 2016. These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), which contemplates continuation of the Company as a going concern. The Company’s principal offices are located at 483 Bay Street, N105, Toronto, Ontario, Canada M5G 2C9 and its U.S. address is 80 Coolidge Hill Road, Watertown, MA. USA 02472. Going Concern As at March 31, 2017, the Company had a working capital deficit of $ 4,375,225 187,156 15,588,554 11,651,980 3,936,574 1,036,148 There is no certainty that the Company will be successful in generating sufficient cash flow from operations or achieving and maintaining profitable operations in the future to enable it to meet its obligations as they come due and consequently continue as a going concern. The Company will require additional financing this year to fund its operations and it is currently working on securing this funding through corporate collaborations, public or private equity offerings or debt financings. Sales of additional equity securities by the Company would result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required. In the event that the necessary additional financing is not obtained, the Company would reduce its discretionary overhead costs substantially or otherwise curtail operations. The Company expects the forgoing, or a combination thereof, to meet the Company’s anticipated cash requirements for the next 12 months; however, these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on recoverability and reclassification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. The consolidated financial statements do not include any adjustments related to the recoverability and classification of the recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. All adjustments, consisting only of normal recurring items, considered necessary for fair presentation have been included in these consolidated financial statements.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. SIGNIFICANT ACCOUNTING POLICIES In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2017. Early adoption is not permitted. The impact on the consolidated financial statements of adopting ASU 2014-09 will be assessed by management. In August 2014, the FASB issued a new financial accounting standard on going concern, ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Sub-Topic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The standard provides guidance about management’s responsibility to evaluate whether there is a substantial doubt about the organization’s ability to continue as a going concern. The amendments in this Update apply to all companies. They become effective in the annual period ending after December 15, 2016, with early application permitted. The Company has adopted this ASU No. 2014-15 as at and for the year ended March 31, 2017. There was no material effect on the consolidated financial position or the consolidated results of operations and comprehensive income (loss). In September 2015, the FASB issued ASU No. 2015-16, “Simplifying the Accounting for Measurement-Period Adjustments,” which illustrates certain guidance governing adjustments to the provisional amounts recognized at the acquisition date with a corresponding adjustment to goodwill. Such adjustments are required when new information is obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement amounts initially recognized or would have resulted in the recognition of additional assets and liabilities. ASU No. 2015-16 eliminates the requirement to retrospectively account for such adjustments. ASU No. 2015-16 is effective for the fiscal year commencing after December 15, 2016. The Company has adopted this ASU No. 2015-16 as at and for the year ended March 31, 2016. There was no material effect on the consolidated financial position or the consolidated results of operations and comprehensive income (loss). In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes,” which requires that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015-17 is effective for the fiscal year commencing after December 15, 2017. The Company does not anticipate that the adoption of ASU No. 2015-17 will have a material effect on the consolidated financial position or the consolidated results of operations. In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The updates makes several modifications to Subtopic 825-10, including the elimination of the available-for-sale classification of equity investments, and it requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in operations. The update is effective for fiscal years beginning after December 2017. The Company is still assessing the impact that the adoption of ASU 2016-01 will have on the consolidated financial position and the consolidated results of operations. In February 2016, the FASB issued ASU 2016-02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASU 2016-02 will have on the consolidated financial position and the consolidated results of operations. In March 2016, the FASB issued ASU 2016-09, “Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting”. Several aspects of the accounting for share-based payment award transaction are simplified, including (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company is still assessing the impact that the adoption of ASU 2016-09 will have on the consolidated financial position and the consolidated results of operations. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for the fiscal year commencing after December 15, 2017. The Company is still assessing the impact that the adoption of ASU 2016-15 will have on the consolidated statement of cash flows. In January 2017, the FASB issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU 2017-01 further states that when substantially all of the fair value of gross assets acquitted is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it is described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after June 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019. Inventory is stated at the lower of cost or market. Cost is recorded at standard cost, which approximates actual cost, on the first-in first-out basis. Work in progress and finished goods consist of materials, labor and allocated overhead. The Company recognizes revenue from product sales when persuasive evidence of an agreement with customer exists, products are shipped or title passes pursuant to the terms of the agreement, the amount due from the customer is fixed or determinable, collectability is reasonably assured, and there are no significant future performance obligation. Deposits are carried as liabilities until the requirements for revenue recognition are met. The Company’s derivative warrant instruments are measured at fair value using a simulation model which takes into account, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock, its expected volatility, holding cost and the risk- free interest rate for the term of the warrant (Note 11). The warrant derivative liability is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss under the caption “Change in fair value of warrant derivative liability”. The selection of the appropriate valuation model and the inputs and assumptions that are required to determine the valuation requires significant judgment and requires management to make estimates and assumptions that affect the reported amount of the related liability and reported amounts of the change in fair value. Actual results could differ from those estimates, and changes in these estimates are recorded when known. As the derivative warrant liability is required to be measured at fair value at each reporting date it is reasonably possible that these estimates and assumptions could change in the near term. The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the balance sheet and amounted to $ 64,957 30,732 On April 1, 2015, Bionik Canada and Bionik Acquisition Inc. changed its functional currency from the Canadian Dollar to the U.S. Dollar. This reflects the fact that the majority of the Company’s business is influenced by an economic environment denominated in U.S. currency as well the Company anticipates revenues to be earned in U.S. dollars. The change in accounting treatment was applied prospectively. The functional currency is separately determined for the Company and each of its subsidiaries, and is used to measure the financial position and operating results. The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction. Equipment is recorded at cost. Depreciation is computed using the declining balance method, over the estimated useful lives of these assets. The costs of improvements that extend the life of equipment are capitalized. All ordinary repair and maintenance costs are expensed as incurred. Property and equipment are depreciated as follows: Computer & Electronics 50% per annum Furniture and Fixtures 20% per annum Demonstration Equipment 50% per annum Manufacturing Equipment 20% per annum Tools and Parts 20% per annum Fair Value of Financial Instruments ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs, which are as observable as possible, and the methods most applicable to the specific situation of each company or valued item. The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, other receivables, accounts payable and accrued liabilities, due from related parties, short term advances, demand loans, convertible loans, promissory note payable and loans receivable approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. As at March 31, 2017 and 2016, the Company’s warrant derivative liability was measured at fair value at each reporting period using a simulation model based on Level 3 inputs. The Company’s policy is to recognize transfers into and out of Level 3 as of the date of the event or change in the circumstances that caused the transfer. There were no such transfers during the year. ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for the way that public business enterprises report information about operating segments in the Company’s consolidated financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company does not have any reportable segments. Cash and cash equivalents include highly liquid investments with original terms to maturity of 90 days or less at the date of purchase. For all periods presented cash and cash equivalents consisted entirely of cash. The Company is engaged in research and development work. Research and development costs are charged as operating expense of the Company as incurred. Income taxes are computed in accordance with the provisions of ASC Topic 740, which requires, among other things, a liability approach to calculating deferred income taxes. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized in its consolidated financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The Company is required to make certain estimates and judgments about the application of tax law, the expected resolution of uncertain tax positions and other matters. In the event that uncertain tax positions are resolved for amounts different than the Company’s estimates, or the related statutes of limitations expire without the assessment of additional income taxes, the Company will be required to adjust the amounts of related assets and liabilities in the period in which such events occur. Such adjustment may have a material impact on the Company’s income tax provision and results of operations. Basic and diluted loss per share has been determined by dividing the net loss available to shareholders for the applicable period by the basic and diluted weighted average number of shares outstanding, respectively. The diluted weighted average number of shares outstanding is calculated as if all dilutive options had been exercised or vested at the later of the beginning of the reporting period or date of grant, using the treasury stock method. Loss per common share is computed by dividing the net loss by the weighted average number of shares of common shares outstanding during the period. Common share equivalents, options and warrants are excluded from the computation of diluted loss per share when their effect is anti-dilutive. The Company follows the ASC Topic 360, which requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable. In performing the review for recoverability, if future undiscounted cash flows (excluding interest charges) from the use and ultimate disposition of the assets are less than their carrying values, an impairment loss represented by the difference between its fair value and carrying value, is recognized. When properties are classified as held for sale they are recorded at the lower of the carrying amount or the expected sales price less costs to sell. The Company records goodwill when the purchase price of an acquisition exceeds the fair value of the net tangible and identified intangible assets acquired. Goodwill and indefinite lived intangible assets, consisting of the trademarks acquired (Note 3), are assessed for impairment annually, or more frequently if indicators of potential impairment exist, which includes evaluating qualitative and quantitative factors to assess the likelihood of an impairment of goodwill or indefinite lived intangible assets. The Company performs impairment tests using a fair value approach when necessary. None of the Company’s goodwill or indefinite lived intangibles were impaired as of March 31, 2017. Accordingly, no impairment loss has been recognized in the year ended March 31, 2017.

ACQUISITION

ACQUISITION	12 Months Ended
	Mar. 31, 2017
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	3. ACQUISITION On April 21, 2016 100 23,650,000 Bionik also assumed each of the 3,895,000 3,000,000 1,000,000 0.25 1,000,000 0.95 1,000,000 1.05 2,582,890 As a result of the acquisition of IMT, the Company acquired assets including three licensed patents, two license agreements, three FDA listed products, a FDA inspected manufacturing facility, extensive clinical and sales data, and international distributors. The Company retained an independent valuator to determine the purchase price allocation, which reflects the allocation of assets and goodwill. As at April 21, 2016 $ Fair value of 23,650,000 shares of common stock (a) 23,177,000 Fair value of vested stock options (b) 2,582,890 Allocation of purchase price: 25,759,890 Cash and cash equivalents 266,635 Accounts receivable 6,490 Inventories 188,879 Prepaid expenses and other current assets 16,839 Equipment 59,749 Liabilities assumed: Accounts payable (241,299) Accrued liabilities (361,029) Customer deposits (86,487) Demand notes payable (324,894) Promissory notes payable (217,808) Bionik advance (d) (1,436,164) Net assets acquired (2,129,089) Patents and exclusive License Agreement 1,306,031 Trademark 2,505,907 Customer relationships 1,431,680 Non compete agreement 61,366 Assembled Workforce 275,720 Goodwill 22,308,275 25,759,890 (a) The fair value of common stock was based on $ 0.98 (b) The fair value of the vested stock options was determined using the Black Scholes option pricing model with the following key assumptions: a risk free rate of 1.59 0 114 (c) Pro forma information has not been presented for IMT as these operation have been consolidated for all days in the year ended March 31, 2017 except 20 days from April 20, 2016. These 20 days are not considered material. Included in the net assets acquired was a loan issued to IMT in the amount of $ 300,000 6 200,000 (e) Amortization Expense Value at March Intangible assets acquired period (years) Value acquired March 31, 2017 31, 2017 $ $ $ Patents and exclusive License Agreement 9.74 1,306,031 126,375 1,179,656 Trademark Indefinite 2,505,907 - 2,505,907 Customer relationships 10 1,431,680 134,931 1,296,749 Non compete agreement 2 61,366 28,918 32,448 Assembled Workforce 1 275,720 259,856 15,864 5,580,704 550,080 5,030,624

PREPAID EXPENSES AND OTHER RECE

PREPAID EXPENSES AND OTHER RECEIVABLES	12 Months Ended
	Mar. 31, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expense And Other Receivables [Text Block]	4. PREPAID EXPENSES AND OTHER RECEIVABLES March 31, March 31, 2017 2016 $ $ Prepaid expenses and other receivables 68,484 87,979 Prepaid insurance 136,896 107,259 Sales taxes receivable (i) 22,667 36,495 228,047 231,733 i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORY

INVENTORY	12 Months Ended
	Mar. 31, 2017
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	5. INVENTORY March 31, March 31, 2017 2016 $ $ Raw Materials 119,985 - Work in Progress 108,264 - 228,249 - For the year ended March 31, 2017, $ 43,009 124,416

EQUIPMENT

EQUIPMENT	12 Months Ended
	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	6. EQUIPMENT March 31, 2017 March 31, 2016 Accumulated Accumulated Cost Depreciation Net Cost Depreciation Net $ $ $ $ $ $ Computers and electronics 250,538 204,258 46,280 152,246 96,379 55,867 Furniture and fixtures 36,795 26,096 10,699 22,496 10,118 12,378 Demonstration equipment 184,586 44,420 140,166 - - - Manufacturing equipment 88,742 84,982 3,760 - - - Tools and parts 11,422 4,472 6,950 11,422 2,917 8,505 Assets under capital lease 23,019 3,453 19,566 - - - Balance, March 31, 2016 595,102 367,681 227,421 186,164 109,414 76,750 Equipment is recorded at cost less accumulated depreciation. Depreciation expense during the year ended March 31, 2017 was $ 79,868 63,454

NOTES PAYABLE

NOTES PAYABLE	12 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	7. NOTES PAYABLE Demand Notes payable The Company has outstanding notes payable (“Notes”) of $ 330,600 3.50 15 150,689 Balance, March 31, 2016 $ - Acquisition of IMT (Note 3) 324,894 Accrued interest 5,706 Balance, March 31, 2017 $ 330,600 Interest expense incurred on the Notes totaled $ 5,706 Promissory Notes payable In February 2014, the Company borrowed $ 200,000 10 18,740 Balance, March 31, 2016 $ - Acquisition of IMT (Note 3) 217,808 Accrued interest 18,740 Balance, March 31, 2017 $ 236,548 Convertible Loans Payable In December 2016, several shareholders of the Company agreed to advance the Company $ 1,500,000 500,000 500,000 500,000 2,000,000 17,488 . The convertible loans contain the following terms: convertible at the option of the holder at the price of the equity financing or payable on demand upon the completion of an equity financing greater than $5,000,000; automatically convertible at the price of the equity financing upon completion of an equity financing between $3,500,000 and $5,000,000 Prior to their maturity, the convertible loans were extended to November 15, 2017 12 10 300,0000 of the convertible loans. No value will be recognized for the warrants until the exercise price is known.

RELATED PARTY TRANSACTIONS AND

RELATED PARTY TRANSACTIONS AND BALANCES	12 Months Ended
	Mar. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	8. RELATED PARTY TRANSACTIONS AND BALANCES Due from related parties As of March 31, 2017 the Company forgave advances receivable from the former Chief Technology Officer (“CTO”) for $ 22,182 41,445 18,731 1 707 Accounts payable and accrued liabilities (b) As at March 31, 2017, $ 4,135 2,694 3,284 12,607 8,812 116 (c) In connection with the acquisition of IMT, the Company acquired an license agreement dated June 8, 2009, with a director as a co-licenser, pursuant to which the Company pays the director and the co-licenser an aggregate royalty of 1 (d) As at March 31, 2017, $ 120,000 15 33,000 (e) As at the effective date of the merger pursuant to the Merger Agreement, a director received an aggregate of 5,190,376 360,231

SHARE CAPITAL

SHARE CAPITAL	12 Months Ended
	Mar. 31, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	9. SHARE CAPITAL March 31, 2017 March 31, 2016 Number of shares $ Number of shares $ Exchangeable Shares: Balance beginning of period 50,000,000 50,000 50,000,000 50,000 Converted into common shares (2,090,664) (2,090) - - Balance at end of period 47,909,336 47,910 50,000,000 50,000 Common Shares Balance at beginning of the period 22,591,292 22,591 22,428,313 22,428 Shares issued on acquisition (Note 3) 23,650,000 23,650 - - Shares issued to exchangeable shareholders 2,090,664 2,090 - - Shares issued for services (f) 217,047 217 117,471 117 Options exercised 110,096 110 - - Warrants exercised 174,759 175 - - Cashless exercise of warrants (iv) 51,249 51 45,508 46 Balance at end of the period 48,885,107 48,884 22,591,292 22,591 TOTAL COMMON SHARES 96,794,443 96,794 72,591,292 72,591 (a) On April 21, 2015, the Company issued 3,115,000 2,492,000 338,960 311,500 0.80 4 435,682 (b) On May 27, 2015, the Company issued 1,418,750 1,135,000 147,566 141,875 0.80 4 37,739 (c) On June 30, 2015, the Company issued 2,035,000 1,628,000 211,656 203,500 0.80 4 74,625 (d) During the year ended March 31, 2016, 53,223 134,248 75,600 (e) During the year ended March 31, 2016, 45,508 148,787 0.80 60,966 (f) During the year ended March 31, 2017, the Company issued 70,000 59,500 60,000 36,000 87,047 62,288 (g) During the year ended March 31, 2017, the Company issued, 51,249 262,045 0.80 (h) On April 21, 2016, the Company acquired 100 23,650,000 (i) During the year ended March 31, 2017, 174,759 40,195 110,096 18,166 (j) During the ended March 31, 2017, holders of 2,090,664 Special Voting Preferred Share In connection with the Merger (Note 1), on February 26, 2015, the Company entered into a voting and exchange trust agreement (the “Trust Agreement”). Pursuant to the Trust Agreement, the Company issued one Special Voting Preferred Share to the Trustee, and the parties created a trust for the Trustee to hold the Special Voting Preferred Share for the benefit of the holders of the Exchangeable Shares (the “Beneficiaries”). Pursuant to the Trust Agreement, the Beneficiaries will have voting rights in the Company equivalent to what they would have had, had they received shares of common stock in the same amount as the Exchangeable Shares held by the Beneficiaries. In connection with the Merger and the Trust Agreement, effective February 20, 2015, the Company filed a certificate of designation of the Special Voting Preferred Share (the “Special Voting Certificate of Designation”) with the Delaware Secretary of State. Pursuant to the Special Voting Certificate of Designation, one share of the Company’s blank check preferred stock was designated as Special Voting Preferred Share. The Special Voting Preferred Share entitles the Trustee to exercise the number of votes equal to the number of Exchangeable Shares outstanding on a one-for-one basis during the term of the Trust Agreement. The Special Voting Preferred Share is not entitled to receive any dividends or to receive any assets of the Company upon liquidation, and is not convertible into shares of common stock of the Company. The voting rights of the Special Voting Preferred Share will terminate pursuant to and in accordance with the Trust Agreement. The Special Voting Preferred Share will be automatically cancelled.

STOCK OPTIONS

STOCK OPTIONS	12 Months Ended
	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	10. STOCK OPTIONS The purpose of the Company’s equity incentive plan, is to attract, retain and motivate persons of training, experience and leadership to the Company, including their directors, officers and employees, and to advance the interests of the Company by providing such persons with the opportunity, through share options, to acquire an increased proprietary interest in the Company. Options or other securities may be granted in respect of authorized and unissued shares, provided that the aggregate number of shares reserved for issuance upon the exercise of all options or other securities granted under the Plan shall not exceed 15% of the shares of common stock and Exchangeable Shares issued and outstanding (determined as of January 1 of each year). Optioned shares in respect of which options are not exercised shall be available for subsequent options. On April 11, 2014 and June 20, 2014, the Company issued 657,430 264,230 0.165 0.23 125,824 531,606 264,230 230,930 118,957 62,912 On July 1, 2014, the Company issued 2,972,592 0.23 7 1,259,487 990,864 On February 17, 2015, the Company issued 314,560 0.23 136,613 110,100 26,164 On November 24, 2015, the Company issued 650,000 694,384 250,000 62,317 142,438 On December 14, 2015, the Company issued 2,495,000 1,260,437 25,000 40,000 407,208 On April 21, 2016, the Company issued 3,000,000 3,895,000 1,000,000 0.25 1,000,000 0.95 1,000,000 1.05 2,582,890 102,989 On April 26, 2016, the Company issued 250,000 1.00 213,750 66,104 On August 8, 2016, the Company issued 750,000 1.00 652,068 140,230 On February 6, 2017, the Company issued 400,000 0.70 245,200 12,163 On February 13, 2017, the Company issued 250,000 0.68 148,750 6,345 During the year ended March 31, 2017, the Company recorded $ 844,162 1,495,837 59,479 Expected life Risk Dividend Forfeiture Expected Grant date Grant date in years free rate rate rate volatility fair value February 17, 2015 4 1.59 % 0 % 0 % 114 % $ 136,613 July 1, 2014 3.35 1.59 % 0 % 0 % 114 % $ 1,259,487 June 20, 2014 5.32 1.59 % 0 % 0 % 114 % $ 118,957 April 11, 2014 3.14 1.59 % 0 % 0 % 114 % $ 230,930 November 24, 2015 6.00 1.59 % 0 % 0 % 114 % $ 694,384 December 14, 2015 6.00 1.59 % 0 % 0 % 114 % $ 1,260,437 April 21, 2016 8.50 1.59 % 0 % 0 % 114 % $ 2,582,890 April 26, 2016 8.50 1.59 % 0 % 0 % 114 % $ 213,750 August 8, 2016 6.30 1.59 % 0 % 0 % 114 % $ 652,068 February 6, 2017 6.86 1.59 % 0 % 0 % 114 % $ 245,200 February 13, 2017 6.86 1.59 % 0 % 0 % 114 % $ 148,750 Weighted-Average Number of Options Exercise Price ($) Outstanding, March 31, 2016 6,604,880 0.57 Issued 4,650,000 0.54 Exercised (110,096) 0.17 Expired (1,037,047) 0.27 Cancelled (204,087) 0.55 Outstanding, March 31, 2017 9,903,650 0.59 Exercise Price ($) Number of Options Expiry Date Exercisable Options 0.165 264,230 April 1, 2021 264,230 0.23 97,514 June 20, 2021 97,514 0.23 1,981,728 July 1, 2021 1,981,728 0.23 204,471 February 17, 2022 204,471 1.22 400,000 November 24, 2022 133,333 1.00 2,400,000 December 14, 2022 809,994 0.95 111,937 March 28, 2023 111,937 1.05 433,027 March 28, 2023 433,027 1.00 250,000 April 26, 2023 - 1.00 750,000 August 8, 2023 - 0.70 400,000 February 6, 2024 - 0.68 250,000 February 13, 2024 - 0.95 31,620 March 3, 2024 31,620 1.05 122,324 March 3, 2024 122,324 0.95 15,810 March 14, 2024 15,810 1.05 61,162 March 14, 2024 61,162 0.95 82,213 September 30, 2024 82,213 1.05 318,042 September 30, 2024 318,042 0.95 7,431 June 2, 2025 7,431 1.05 28,747 June 2, 2025 28,747 0.25 906,077 July 28, 2025 906,077 0.95 671,859 July 29, 2025 671,859 0.25 66,298 December 30, 2025 53,909 0.95 49,160 December 30, 2025 27,261 9,903,650 6,362,689 The weighted-average remaining contractual term of the outstanding options is 5.12 5.89 6.02 5.26

WARRANTS

WARRANTS	12 Months Ended
	Mar. 31, 2017
Warrants and Rights Note Disclosure [Abstract]
Shareholders Equity And Share Based Payments Stock Warrant [Text Block]	11. WARRANTS Weighted-Average Number of Warrants Exercise Price ($) Outstanding and exercisable, March 31, 2015 10,823,450 1.35 Issued 7,225,625 1.35 Exercised (148,787) (0.80) Outstanding and exercisable, March 31, 2016 17,900,288 1.35 Exercised (262,045) (0.80) Outstanding and exercisable, March 31, 2017 17,638,243 1.35 During the year ended March 31, 2017 a warrant holder exercised 262,045 51,249 During the year ended March 31, 2016, a warrant holder exercised 148,787 45,508 Common share purchase warrants Exercise Number of Price ($) Warrants Expiry Date 1.40 7,735,750 February 26, 2019 1.40 1,212,500 March 27, 2019 1.40 891,250 March 31, 2019 1.40 3,115,000 April 21, 2019 1.40 1,418,750 May 27, 2019 1.40 2,035,000 June 30, 2019 0.80 1,229,993 February 26, 2019 17,638,243 The weighted-average remaining contractual term of the outstanding warrants was 1.77 2.77 Exchangeable share purchase warrants In 2014, the Company repaid loans of $ 180,940 12,138 349,522 0.23 In March 2017, 174,759 40,195 174,763 Warrant derivative liability The Company’s outstanding common share purchase warrants include price protection provisions that allow for a reduction in the exercise price of the warrants in the event the Company subsequently issues common stock or options, rights, warrants or securities convertible or exchangeable for shares of common stock at a price lower than the exercise price of the warrants. Simultaneously with any reduction to the exercise price, the number of shares of common stock that may be purchased upon exercise of each of these warrants shall be increased based on a pre-defined formula. In addition, prior to the effectiveness of certain resale registration statements or if any such registration statements are no longer effective, the holder of the Company’s warrants, at their option, may exercise all or any part of the warrants in a “cashless” or “net-issue” exercise. The Company has the option to redeem the warrants for $0.001 per warrant if the daily volume weighted-average price of the common shares is 200% or more of the exercise price for twenty consecutive trading days provided there is an effective registration statement covering the shares of common stock available throughout the thirty day period after the redemption date. The warrant holders then have thirty days to exercise the warrants or receive the redemption amount. The Company’s derivative instruments have been measured at fair value at inception and at each reporting period using a simulation model. The Company recognizes all of its warrants with price protection on its consolidated balance sheet as a derivative liability. Number of Warrants Value ($) Warrants issued in February 26, 2015 financing 8,509,325 550,374 Warrants issued in March 27, 2015 financing 1,333,750 1,036,325 Warrants issued in March 31, 2015 financing 980,375 759,290 Change in fair value of warrant derivative liability 6,036,659 Balance at March 31, 2015 8,382,648 Warrants issued in April 21, 2015 financing Note 9(a) 3,426,500 2,588,722 Warrants issued in May 27, 2015 financing Note 9(b) 1,560,625 1,025,173 Warrants issued in June 30, 2015 financing Note 9(c) 2,238,500 1,490,969 Change in fair value of warrant derivative liability (8,290,556) Fair value of warrants exercised (60,966) Balance at March 31, 2016 5,135,990 Change in fair value of warrant derivative liability (4,176,390) Balance at March 31, 2017 959,600 During the year ended March 31, 2017, the Company recorded a gain of $ 4,176,230 8,290,556 4,176,230 Expected Exercise Risk Number of life in Price free Dividend Expected Fair Grant date Warrants years ($) Rate rate volatility value ($) At Inception: February 26, 2015 7,735,750 4 1.4 0.44 % 0 % 51.83 % 464,784 February 26, 2015 773,575 4 0.8 0.44 % 0 % 51.83 % 85,590 March 27, 2015 1,212,500 3.92 1.4 0.43 % 0 % 52.37 % 950,913 March 27, 2015 121,250 3.92 0.8 0.43 % 0 % 52.37 % 85,412 March 31, 2015 891,250 3.91 1.4 0.41 % 0 % 52.45 % 696,582 March 31, 2015 89,125 3.91 0.8 0.41 % 0 % 52.45 % 62,708 April 21, 2015 3,115,000 3.85 1.4 0.68 % 0 % 51.54 % 2,371,956 April 21, 2015 311,500 3.85 0.8 0.68 % 0 % 51.54 % 216,766 May 27, 2015 1,418,750 3.76 1.4 0.46 % 0 % 51.74 % 933,065 May 27, 2015 141,875 3.76 0.8 0.46 % 0 % 51.74 % 92,108 June 30, 2015 2,035,000 3.66 1.4 0.37 % 0 % 52.94 % 1,356,512 June 30, 2015 203,500 3.66 0.8 0.37 % 0 % 52.94 % 134,457 At Year end: March 31, 2016 16,408,250 2.91 1.4 0.21 % 0 % 62.96 % 4,585,539 March 31, 2016 1,492,038 2.91 0.8 0.21 % 0 % 62.96 % 550,451 At Year end: March 31, 2017 16,408,250 1.91 1.4 0.65 % 0 % 53.58 % 849,713 March 31, 2017 1,229,993 1.91 0.8 0.65 % 0 % 53.58 % 109,887 In addition to the forgoing, the Company also utilized a holding cost to approximate the impact of a holder of the warrant to maintain a hedging strategy in which they maintained a short position. On analysis of comparable companies and other information the Company has determined that the use of 2.25 The warrant derivative liability is classified within Level 3 of the fair value hierarchy because on initial recognition and again at each reporting period, it was valued using these significant inputs and assumptions that are unobservable in the market. Changes in the values assumed and used in the simulation model can materially affect the estimate of fair value. Generally, an increase in the market price of the Company’s shares of common stock, an increase in the volatility of the Company’s shares of common stock and an increase in the expected life would result in a directionally similar change in the estimated fair value of the warrant derivative liability. An increase in the risk free rate would result in a decrease in the fair value of the warrant derivative liability. The expected life is based on the remaining contractual term of the warrants. The risk free rate was based on U.S. treasury-note yields with terms commensurate with the remaining term of the warrants. Expected volatility over the expected term of the warrants is estimated based on consideration of historical volatility and other information. In addition to the assumptions above, the Company also took into consideration the probability of the Company’s participation in another round of financing, the type of such financing and the range of the stock price for the financing at that time. At each increment of the simulation, the daily volume weighted-average price was calculated. If this amount was 200

INCOME TAXES

INCOME TAXES	12 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	12. INCOME TAXES Year Year ended ended March 31, March 31, 2017 2016 $ $ U.S. (1,923,556) 4,706,413 Canada (2,013,018) (3,670,265) (3,936,574) 1,036,148 Year Year ended ended March 31, March 31, 2017 2016 $ $ Net (loss) income for the year before recovery of income taxes (3,936,574) (1,036,148) Statutory rate 35 % 35 % Expected income tax (recovery) expense (1,377,801) 362,652 Tax rate changes and other basis adjustments 59,484 195,108 Change in fair value of derivative liability (1,461,681) (2,709,894) Stock-based compensation 350,683 512,693 Non-deductible expenses (132,076) (12,073) Net DTA acquired (546,122) - Change in valuation allowance 3,107,513 1,651,514 Recovery of income taxes - - March 31, March 31, 2017 2016 $ $ Equipment 73,520 52,331 Share issue costs 1,456 3,586 SR&ED pool 464,746 400,557 Other 629,266 215,202 Non-capital losses – Canada 2,067,203 1,587,439 Net operating losses - U.S. 4,534,710 589,491 Valuation allowance (5,956,118) (2,848,606) 1,814,783 - Intangibles and other (1,814,783) - - - The Company has non-capital losses in its Canadian subsidiary of approximately $ 7,800,000 3,513,000 8,620,000 Income taxes are provided based on the liability method, which results in deferred tax assets and liabilities arising from temporary differences. Temporary differences are differences between the tax basis of assets and liabilities and their reported amounts in the consolidated financial statements that will result in taxable or deductible amounts in future years. The liability method requires the effect of tax rate changes on current and accumulated deferred taxes to be reflected in the period in which the rate change was enacted. The liability method also requires that deferred tax assets be reduced by a valuation allowance unless it is more likely than not that the assets will be realized. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest accrued on uncertain tax positions as well as interest received from favorable tax settlements within interest expense. The Company recognizes penalties accrued on unrecognized tax benefits within general and administrative expenses. As of March 31, 2017, the Company had no uncertain tax positions. United States – Federal 2013 – present United States – State 2013 – present Canada – Federal 2012 – present Canada – Provincial 2012 – present

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	13. COMMITMENTS AND CONTINGENCIES Contingencies From time to time, the Company may be involved in a variety of claims, suits, investigations and proceedings arising in the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, the Company believes that the resolution of current pending matters will not have a material adverse effect on its business, financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on the Company because of legal costs, diversion of management resources and other factors. Commitments On February 25, 2015, 262,904 241,185 210,323 314,560 320,000

RISK MANAGEMENT

RISK MANAGEMENT	12 Months Ended
	Mar. 31, 2017
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	14. RISK MANAGEMENT The Company’s cash balances are maintained in two banks in Canada and a Canadian Bank subsidiary in the US. Deposits held in banks in Canada are insured up to $ 100,000 Interest Rate Risk Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in the interest rates. The Company has minimal exposure to fluctuations in the market interest rate. In seeking to minimize the risks from interest rate fluctuations, the Company manages exposure through its normal operating and financing activities. Liquidity Risk Liquidity risk is the risk that the Company will incur difficulties meeting its financial obligations, as they are due. The Company’s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due. Accounts payable and accrued liabilities are due within the current operating period. The Company has funded its operations through the issuance of capital stock, convertible debt and loans in addition to grants and investment tax credits received from the Government of Canada.

(LOSS) PER SHARE

(LOSS) PER SHARE	12 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	15 (LOSS) PER SHARE Common stock equivalents (other than the Exchangeable Shares), options and warrants were excluded from the computation of diluted loss per share for the year ended March 31, 2017 (as their effects are anti-dilutive). Numerator Net loss $ (1,036,148) Change in fair value of warrant derivative liability (7,742,555) Net (loss) used in computation of diluted EPS $ (6,706,407) Denominator Basic weighted average number of shares outstanding 71,554,822 Warrants 8,429,435 Diluted weighted average number of shares outstanding 79,984,257 Diluted loss per share $ (0.08)

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events [Text Block]	16. SUBSEQUENT EVENTS 1. On May 23, 2017, the Company entered into a Co-operative Joint Venture Contract (the “JV Agreement”) with Ginger Capital Investment Holding Ltd., a Hong Kong corporation (“Ginger Capital”), to establish a cooperative joint venture enterprise in the People’s Republic of China. The joint venture was established for the purposes of strengthening the economic cooperation and technical exchange between the parties and adopting advanced technology and scientific management methods through the distribution and promotion of the Company’s products in the People’s Republic of China, Hong Kong and Macau (the “Territory”). The registered capital of the joint venture will be ten million RMB or approximately US$ 1.45 Any profit distribution will be 75% in favor of Ginger Capital and 25% in favor of the Company 500,000 8 3,000,000 (i) $0.50 per New Round Stock and (ii) the quotient obtained by dividing (x) the Outstanding Balance on the conversion date multiplied by 1.10 by (y) the actual price per New Round Stock in the Qualified Financing. Upon the Maturity Date, Ginger Capital shall further be issued the Warrant, exercisable into a number of shares of the Company’s common stock equal to (i) in the case of the conversion of the Note, 25% of the number of shares issued upon conversion and (ii) in the case of the repayment of the Note in cash, the number of shares of Common Stock equal to the quotient obtained by dividing the Outstanding Balance by 4. The exercise price per share is $0.60. 2. On June 22, 2017, the Company entered into a Joint Development and Manufacturing Agreement with Wistron Medical Tech Holding Company (“Wistron”), pursuant to which the parties agreed to jointly design, engineer, and manufacture low-price, lower-body assistive robotic technologies for mass commercial sale within the consumer home products market (the “Joint Development Agreement”). Pursuant to the Joint Development Agreement, among other things, each party granted to the other a fully paid up, non-exclusive, royalty-free, non -transferable and non-sublicensable license under its background intellectual property to (i) develop the joint development product for commercialization and use; and (ii) use or manufacture, as the case may be, the joint development product to perform its obligations under the Joint Development Agreement. Additionally, the Company agreed to reimburse Wistron for all of its costs and expenses under the Joint Development Agreement (either through a mark-up on the cost of goods or through a payment for costs incurred), and shall own all developed intellectual property so long as the reimbursement obligations have been met. 3. On May 25, 2017, the Company commenced an offer to amend and exercise to all of the holders of its $ 1.40 0.80 0.25 5.0 1,250,000 125,000 12.7

SIGNIFICANT ACCOUNTING POLICI24

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Recently Adopted Accounting Pronouncements [Policy Text Block]	Newly Adopted and Recently Issued Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2017. Early adoption is not permitted. The impact on the consolidated financial statements of adopting ASU 2014-09 will be assessed by management. In August 2014, the FASB issued a new financial accounting standard on going concern, ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Sub-Topic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The standard provides guidance about management’s responsibility to evaluate whether there is a substantial doubt about the organization’s ability to continue as a going concern. The amendments in this Update apply to all companies. They become effective in the annual period ending after December 15, 2016, with early application permitted. The Company has adopted this ASU No. 2014-15 as at and for the year ended March 31, 2017. There was no material effect on the consolidated financial position or the consolidated results of operations and comprehensive income (loss). In September 2015, the FASB issued ASU No. 2015-16, “Simplifying the Accounting for Measurement-Period Adjustments,” which illustrates certain guidance governing adjustments to the provisional amounts recognized at the acquisition date with a corresponding adjustment to goodwill. Such adjustments are required when new information is obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement amounts initially recognized or would have resulted in the recognition of additional assets and liabilities. ASU No. 2015-16 eliminates the requirement to retrospectively account for such adjustments. ASU No. 2015-16 is effective for the fiscal year commencing after December 15, 2016. The Company has adopted this ASU No. 2015-16 as at and for the year ended March 31, 2016. There was no material effect on the consolidated financial position or the consolidated results of operations and comprehensive income (loss). In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes,” which requires that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015-17 is effective for the fiscal year commencing after December 15, 2017. The Company does not anticipate that the adoption of ASU No. 2015-17 will have a material effect on the consolidated financial position or the consolidated results of operations. In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The updates makes several modifications to Subtopic 825-10, including the elimination of the available-for-sale classification of equity investments, and it requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in operations. The update is effective for fiscal years beginning after December 2017. The Company is still assessing the impact that the adoption of ASU 2016-01 will have on the consolidated financial position and the consolidated results of operations. In February 2016, the FASB issued ASU 2016-02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASU 2016-02 will have on the consolidated financial position and the consolidated results of operations. In March 2016, the FASB issued ASU 2016-09, “Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting”. Several aspects of the accounting for share-based payment award transaction are simplified, including (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company is still assessing the impact that the adoption of ASU 2016-09 will have on the consolidated financial position and the consolidated results of operations. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for the fiscal year commencing after December 15, 2017. The Company is still assessing the impact that the adoption of ASU 2016-15 will have on the consolidated statement of cash flows. In January 2017, the FASB issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU 2017-01 further states that when substantially all of the fair value of gross assets acquitted is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it is described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after June 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019.
Inventory, Policy [Policy Text Block]	Inventory Inventory is stated at the lower of cost or market. Cost is recorded at standard cost, which approximates actual cost, on the first-in first-out basis. Work in progress and finished goods consist of materials, labor and allocated overhead.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue from product sales when persuasive evidence of an agreement with customer exists, products are shipped or title passes pursuant to the terms of the agreement, the amount due from the customer is fixed or determinable, collectability is reasonably assured, and there are no significant future performance obligation. Deposits are carried as liabilities until the requirements for revenue recognition are met.
Warrant Derivative Liability Policy [Policy Text Block]	Significant Judgments – Warrant Derivative Liability The Company’s derivative warrant instruments are measured at fair value using a simulation model which takes into account, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock, its expected volatility, holding cost and the risk- free interest rate for the term of the warrant (Note 11). The warrant derivative liability is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss under the caption “Change in fair value of warrant derivative liability”. The selection of the appropriate valuation model and the inputs and assumptions that are required to determine the valuation requires significant judgment and requires management to make estimates and assumptions that affect the reported amount of the related liability and reported amounts of the change in fair value. Actual results could differ from those estimates, and changes in these estimates are recorded when known. As the derivative warrant liability is required to be measured at fair value at each reporting date it is reasonably possible that these estimates and assumptions could change in the near term.
Standard Product Warranty, Policy [Policy Text Block]	Warranty Reserve and Deferred Warranty Revenue The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the balance sheet and amounted to $ 64,957 30,732
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation On April 1, 2015, Bionik Canada and Bionik Acquisition Inc. changed its functional currency from the Canadian Dollar to the U.S. Dollar. This reflects the fact that the majority of the Company’s business is influenced by an economic environment denominated in U.S. currency as well the Company anticipates revenues to be earned in U.S. dollars. The change in accounting treatment was applied prospectively. The functional currency is separately determined for the Company and each of its subsidiaries, and is used to measure the financial position and operating results. The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.
Property, Plant and Equipment, Policy [Policy Text Block]	Equipment is recorded at cost. Depreciation is computed using the declining balance method, over the estimated useful lives of these assets. The costs of improvements that extend the life of equipment are capitalized. All ordinary repair and maintenance costs are expensed as incurred. Property and equipment are depreciated as follows: Computer & Electronics 50% per annum Furniture and Fixtures 20% per annum Demonstration Equipment 50% per annum Manufacturing Equipment 20% per annum Tools and Parts 20% per annum
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs, which are as observable as possible, and the methods most applicable to the specific situation of each company or valued item. The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, other receivables, accounts payable and accrued liabilities, due from related parties, short term advances, demand loans, convertible loans, promissory note payable and loans receivable approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. As at March 31, 2017 and 2016, the Company’s warrant derivative liability was measured at fair value at each reporting period using a simulation model based on Level 3 inputs. The Company’s policy is to recognize transfers into and out of Level 3 as of the date of the event or change in the circumstances that caused the transfer. There were no such transfers during the year.
Segment Reporting, Policy [Policy Text Block]	Segment Reporting ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for the way that public business enterprises report information about operating segments in the Company’s consolidated financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company does not have any reportable segments.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Cash and cash equivalents include highly liquid investments with original terms to maturity of 90 days or less at the date of purchase. For all periods presented cash and cash equivalents consisted entirely of cash.
Research and Development Expense, Policy [Policy Text Block]	Research and Development The Company is engaged in research and development work. Research and development costs are charged as operating expense of the Company as incurred.
Income Tax, Policy [Policy Text Block]	Income Taxes Income taxes are computed in accordance with the provisions of ASC Topic 740, which requires, among other things, a liability approach to calculating deferred income taxes. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized in its consolidated financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The Company is required to make certain estimates and judgments about the application of tax law, the expected resolution of uncertain tax positions and other matters. In the event that uncertain tax positions are resolved for amounts different than the Company’s estimates, or the related statutes of limitations expire without the assessment of additional income taxes, the Company will be required to adjust the amounts of related assets and liabilities in the period in which such events occur. Such adjustment may have a material impact on the Company’s income tax provision and results of operations.
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Loss Per Share Basic and diluted loss per share has been determined by dividing the net loss available to shareholders for the applicable period by the basic and diluted weighted average number of shares outstanding, respectively. The diluted weighted average number of shares outstanding is calculated as if all dilutive options had been exercised or vested at the later of the beginning of the reporting period or date of grant, using the treasury stock method. Loss per common share is computed by dividing the net loss by the weighted average number of shares of common shares outstanding during the period. Common share equivalents, options and warrants are excluded from the computation of diluted loss per share when their effect is anti-dilutive.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company follows the ASC Topic 360, which requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable. In performing the review for recoverability, if future undiscounted cash flows (excluding interest charges) from the use and ultimate disposition of the assets are less than their carrying values, an impairment loss represented by the difference between its fair value and carrying value, is recognized. When properties are classified as held for sale they are recorded at the lower of the carrying amount or the expected sales price less costs to sell.
Goodwill and Intangible Assets, Policy [Policy Text Block]	The Company records goodwill when the purchase price of an acquisition exceeds the fair value of the net tangible and identified intangible assets acquired. Goodwill and indefinite lived intangible assets, consisting of the trademarks acquired (Note 3), are assessed for impairment annually, or more frequently if indicators of potential impairment exist, which includes evaluating qualitative and quantitative factors to assess the likelihood of an impairment of goodwill or indefinite lived intangible assets. The Company performs impairment tests using a fair value approach when necessary. None of the Company’s goodwill or indefinite lived intangibles were impaired as of March 31, 2017. Accordingly, no impairment loss has been recognized in the year ended March 31, 2017.

ACQUISITION (Tables)

ACQUISITION (Tables)	12 Months Ended
	Mar. 31, 2017
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	As at April 21, 2016 $ Fair value of 23,650,000 shares of common stock (a) 23,177,000 Fair value of vested stock options (b) 2,582,890 Allocation of purchase price: 25,759,890 Cash and cash equivalents 266,635 Accounts receivable 6,490 Inventories 188,879 Prepaid expenses and other current assets 16,839 Equipment 59,749 Liabilities assumed: Accounts payable (241,299) Accrued liabilities (361,029) Customer deposits (86,487) Demand notes payable (324,894) Promissory notes payable (217,808) Bionik advance (d) (1,436,164) Net assets acquired (2,129,089) Patents and exclusive License Agreement 1,306,031 Trademark 2,505,907 Customer relationships 1,431,680 Non compete agreement 61,366 Assembled Workforce 275,720 Goodwill 22,308,275 25,759,890 (a) The fair value of common stock was based on $ 0.98 (b) The fair value of the vested stock options was determined using the Black Scholes option pricing model with the following key assumptions: a risk free rate of 1.59 0 114 (c) Pro forma information has not been presented for IMT as these operation have been consolidated for all days in the year ended March 31, 2017 except 20 days from April 20, 2016. These 20 days are not considered material. Included in the net assets acquired was a loan issued to IMT in the amount of $ 300,000 6 200,000
Business Acquisition, Pro Forma Information [Table Text Block]	The schedule below reflects the intangible assets acquired in the IMT acquisition and the assets amortization period and expense for the year ended March 31, 2017: Amortization Expense Value at March Intangible assets acquired period (years) Value acquired March 31, 2017 31, 2017 $ $ $ Patents and exclusive License Agreement 9.74 1,306,031 126,375 1,179,656 Trademark Indefinite 2,505,907 - 2,505,907 Customer relationships 10 1,431,680 134,931 1,296,749 Non compete agreement 2 61,366 28,918 32,448 Assembled Workforce 1 275,720 259,856 15,864 5,580,704 550,080 5,030,624

PREPAID EXPENSES AND OTHER RE26

PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)	12 Months Ended
	Mar. 31, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	March 31, March 31, 2017 2016 $ $ Prepaid expenses and other receivables 68,484 87,979 Prepaid insurance 136,896 107,259 Sales taxes receivable (i) 22,667 36,495 228,047 231,733 i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORY (Tables)

INVENTORY (Tables)	12 Months Ended
	Mar. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	March 31, March 31, 2017 2016 $ $ Raw Materials 119,985 - Work in Progress 108,264 - 228,249 -

EQUIPMENT (Tables)

EQUIPMENT (Tables)	12 Months Ended
	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Equipment consisted of the following as at March 31, 2017 and March 31 2016: March 31, 2017 March 31, 2016 Accumulated Accumulated Cost Depreciation Net Cost Depreciation Net $ $ $ $ $ $ Computers and electronics 250,538 204,258 46,280 152,246 96,379 55,867 Furniture and fixtures 36,795 26,096 10,699 22,496 10,118 12,378 Demonstration equipment 184,586 44,420 140,166 - - - Manufacturing equipment 88,742 84,982 3,760 - - - Tools and parts 11,422 4,472 6,950 11,422 2,917 8,505 Assets under capital lease 23,019 3,453 19,566 - - - Balance, March 31, 2016 595,102 367,681 227,421 186,164 109,414 76,750

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	12 Months Ended
	Mar. 31, 2017
Demand Notes payable [Member]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Balance, March 31, 2016 $ - Acquisition of IMT (Note 3) 324,894 Accrued interest 5,706 Balance, March 31, 2017 $ 330,600
Promissory Note [Member]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Balance, March 31, 2016 $ - Acquisition of IMT (Note 3) 217,808 Accrued interest 18,740 Balance, March 31, 2017 $ 236,548

SHARE CAPITAL (Tables)

SHARE CAPITAL (Tables)	12 Months Ended
	Mar. 31, 2017
Stockholders' Equity Note [Abstract]
Schedule of Stockholders Equity [Table Text Block]	March 31, 2017 March 31, 2016 Number of shares $ Number of shares $ Exchangeable Shares: Balance beginning of period 50,000,000 50,000 50,000,000 50,000 Converted into common shares (2,090,664) (2,090) - - Balance at end of period 47,909,336 47,910 50,000,000 50,000 Common Shares Balance at beginning of the period 22,591,292 22,591 22,428,313 22,428 Shares issued on acquisition (Note 3) 23,650,000 23,650 - - Shares issued to exchangeable shareholders 2,090,664 2,090 - - Shares issued for services (f) 217,047 217 117,471 117 Options exercised 110,096 110 - - Warrants exercised 174,759 175 - - Cashless exercise of warrants (iv) 51,249 51 45,508 46 Balance at end of the period 48,885,107 48,884 22,591,292 22,591 TOTAL COMMON SHARES 96,794,443 96,794 72,591,292 72,591 (a) On April 21, 2015, the Company issued 3,115,000 2,492,000 338,960 311,500 0.80 4 435,682 (b) On May 27, 2015, the Company issued 1,418,750 1,135,000 147,566 141,875 0.80 4 37,739 (c) On June 30, 2015, the Company issued 2,035,000 1,628,000 211,656 203,500 0.80 4 74,625 (d) During the year ended March 31, 2016, 53,223 134,248 75,600 (e) During the year ended March 31, 2016, 45,508 148,787 0.80 60,966 (f) During the year ended March 31, 2017, the Company issued 70,000 59,500 60,000 36,000 87,047 62,288 (g) During the year ended March 31, 2017, the Company issued, 51,249 262,045 0.80 (h) On April 21, 2016, the Company acquired 100 23,650,000 (i) During the year ended March 31, 2017, 174,759 40,195 110,096 18,166 (j) During the ended March 31, 2017, holders of 2,090,664

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	12 Months Ended
	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	These options at their respective grant dates were valued using the Black-Scholes option pricing model with the following key assumptions: Expected life Risk Dividend Forfeiture Expected Grant date Grant date in years free rate rate rate volatility fair value February 17, 2015 4 1.59 % 0 % 0 % 114 % $ 136,613 July 1, 2014 3.35 1.59 % 0 % 0 % 114 % $ 1,259,487 June 20, 2014 5.32 1.59 % 0 % 0 % 114 % $ 118,957 April 11, 2014 3.14 1.59 % 0 % 0 % 114 % $ 230,930 November 24, 2015 6.00 1.59 % 0 % 0 % 114 % $ 694,384 December 14, 2015 6.00 1.59 % 0 % 0 % 114 % $ 1,260,437 April 21, 2016 8.50 1.59 % 0 % 0 % 114 % $ 2,582,890 April 26, 2016 8.50 1.59 % 0 % 0 % 114 % $ 213,750 August 8, 2016 6.30 1.59 % 0 % 0 % 114 % $ 652,068 February 6, 2017 6.86 1.59 % 0 % 0 % 114 % $ 245,200 February 13, 2017 6.86 1.59 % 0 % 0 % 114 % $ 148,750
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted-Average Number of Options Exercise Price ($) Outstanding, March 31, 2016 6,604,880 0.57 Issued 4,650,000 0.54 Exercised (110,096) 0.17 Expired (1,037,047) 0.27 Cancelled (204,087) 0.55 Outstanding, March 31, 2017 9,903,650 0.59
Share-based Compensation, Performance Shares Award Outstanding Activity [Table Text Block]	The following is a summary of stock options outstanding and exercisable as of March 31, 2017: Exercise Price ($) Number of Options Expiry Date Exercisable Options 0.165 264,230 April 1, 2021 264,230 0.23 97,514 June 20, 2021 97,514 0.23 1,981,728 July 1, 2021 1,981,728 0.23 204,471 February 17, 2022 204,471 1.22 400,000 November 24, 2022 133,333 1.00 2,400,000 December 14, 2022 809,994 0.95 111,937 March 28, 2023 111,937 1.05 433,027 March 28, 2023 433,027 1.00 250,000 April 26, 2023 - 1.00 750,000 August 8, 2023 - 0.70 400,000 February 6, 2024 - 0.68 250,000 February 13, 2024 - 0.95 31,620 March 3, 2024 31,620 1.05 122,324 March 3, 2024 122,324 0.95 15,810 March 14, 2024 15,810 1.05 61,162 March 14, 2024 61,162 0.95 82,213 September 30, 2024 82,213 1.05 318,042 September 30, 2024 318,042 0.95 7,431 June 2, 2025 7,431 1.05 28,747 June 2, 2025 28,747 0.25 906,077 July 28, 2025 906,077 0.95 671,859 July 29, 2025 671,859 0.25 66,298 December 30, 2025 53,909 0.95 49,160 December 30, 2025 27,261 9,903,650 6,362,689

WARRANTS (Tables)

WARRANTS (Tables)	12 Months Ended
	Mar. 31, 2017
Warrants and Rights Note Disclosure [Abstract]
Schedule Of Share Based Compensation Stock Purchase Warrants Activity [Table Text Block]	The following is a continuity schedule of the Company’s common share purchase warrants: Weighted-Average Number of Warrants Exercise Price ($) Outstanding and exercisable, March 31, 2015 10,823,450 1.35 Issued 7,225,625 1.35 Exercised (148,787) (0.80) Outstanding and exercisable, March 31, 2016 17,900,288 1.35 Exercised (262,045) (0.80) Outstanding and exercisable, March 31, 2017 17,638,243 1.35
Schedule of Common Share Purchase Warrants Outstanding [Table Text Block]	The following is a summary of common share purchase warrants outstanding as of March 31, 2017: Exercise Number of Price ($) Warrants Expiry Date 1.40 7,735,750 February 26, 2019 1.40 1,212,500 March 27, 2019 1.40 891,250 March 31, 2019 1.40 3,115,000 April 21, 2019 1.40 1,418,750 May 27, 2019 1.40 2,035,000 June 30, 2019 0.80 1,229,993 February 26, 2019 17,638,243
Schedule Of Warrant derivative liability [Table Text Block]	The following summarizes the changes in the value of the warrant derivative liability from inception until March 31, 2017: Number of Warrants Value ($) Warrants issued in February 26, 2015 financing 8,509,325 550,374 Warrants issued in March 27, 2015 financing 1,333,750 1,036,325 Warrants issued in March 31, 2015 financing 980,375 759,290 Change in fair value of warrant derivative liability 6,036,659 Balance at March 31, 2015 8,382,648 Warrants issued in April 21, 2015 financing Note 9(a) 3,426,500 2,588,722 Warrants issued in May 27, 2015 financing Note 9(b) 1,560,625 1,025,173 Warrants issued in June 30, 2015 financing Note 9(c) 2,238,500 1,490,969 Change in fair value of warrant derivative liability (8,290,556) Fair value of warrants exercised (60,966) Balance at March 31, 2016 5,135,990 Change in fair value of warrant derivative liability (4,176,390) Balance at March 31, 2017 959,600
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	The key inputs and assumptions used in the simulation model at inception and at March 31, 2017 and 2016 are as follows: Expected Exercise Risk Number of life in Price free Dividend Expected Fair Grant date Warrants years ($) Rate rate volatility value ($) At Inception: February 26, 2015 7,735,750 4 1.4 0.44 % 0 % 51.83 % 464,784 February 26, 2015 773,575 4 0.8 0.44 % 0 % 51.83 % 85,590 March 27, 2015 1,212,500 3.92 1.4 0.43 % 0 % 52.37 % 950,913 March 27, 2015 121,250 3.92 0.8 0.43 % 0 % 52.37 % 85,412 March 31, 2015 891,250 3.91 1.4 0.41 % 0 % 52.45 % 696,582 March 31, 2015 89,125 3.91 0.8 0.41 % 0 % 52.45 % 62,708 April 21, 2015 3,115,000 3.85 1.4 0.68 % 0 % 51.54 % 2,371,956 April 21, 2015 311,500 3.85 0.8 0.68 % 0 % 51.54 % 216,766 May 27, 2015 1,418,750 3.76 1.4 0.46 % 0 % 51.74 % 933,065 May 27, 2015 141,875 3.76 0.8 0.46 % 0 % 51.74 % 92,108 June 30, 2015 2,035,000 3.66 1.4 0.37 % 0 % 52.94 % 1,356,512 June 30, 2015 203,500 3.66 0.8 0.37 % 0 % 52.94 % 134,457 At Year end: March 31, 2016 16,408,250 2.91 1.4 0.21 % 0 % 62.96 % 4,585,539 March 31, 2016 1,492,038 2.91 0.8 0.21 % 0 % 62.96 % 550,451 At Year end: March 31, 2017 16,408,250 1.91 1.4 0.65 % 0 % 53.58 % 849,713 March 31, 2017 1,229,993 1.91 0.8 0.65 % 0 % 53.58 % 109,887

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Components of net (loss) income before income taxes consists of the following: Year Year ended ended March 31, March 31, 2017 2016 $ $ U.S. (1,923,556) 4,706,413 Canada (2,013,018) (3,670,265) (3,936,574) 1,036,148 Year Year ended ended March 31, March 31, 2017 2016 $ $ Net (loss) income for the year before recovery of income taxes (3,936,574) (1,036,148) Statutory rate 35 % 35 % Expected income tax (recovery) expense (1,377,801) 362,652 Tax rate changes and other basis adjustments 59,484 195,108 Change in fair value of derivative liability (1,461,681) (2,709,894) Stock-based compensation 350,683 512,693 Non-deductible expenses (132,076) (12,073) Net DTA acquired (546,122) - Change in valuation allowance 3,107,513 1,651,514 Recovery of income taxes - -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The following deferred tax assets have not been recognized. Deferred tax reflects the tax effects of temporary differences that gave rise to significant portions of deferred tax assets and liabilities and consisted of the following: March 31, March 31, 2017 2016 $ $ Equipment 73,520 52,331 Share issue costs 1,456 3,586 SR&ED pool 464,746 400,557 Other 629,266 215,202 Non-capital losses – Canada 2,067,203 1,587,439 Net operating losses - U.S. 4,534,710 589,491 Valuation allowance (5,956,118) (2,848,606) 1,814,783 - Intangibles and other (1,814,783) - - -
Summary of Income Tax Examinations [Table Text Block]	United States – Federal 2013 – present United States – State 2013 – present Canada – Federal 2012 – present Canada – Provincial 2012 – present

(LOSS) PER SHARE (Tables)

(LOSS) PER SHARE (Tables)	12 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]	The reconciliation of diluted (loss) per share for the year ended March 31, 2016 is presented below: Numerator Net loss $ (1,036,148) Change in fair value of warrant derivative liability (7,742,555) Net (loss) used in computation of diluted EPS $ (6,706,407) Denominator Basic weighted average number of shares outstanding 71,554,822 Warrants 8,429,435 Diluted weighted average number of shares outstanding 79,984,257 Diluted loss per share $ (0.08)

NATURE OF OPERATIONS AND GOIN35

NATURE OF OPERATIONS AND GOING CONCERN (Details Textual)	1 Months Ended		12 Months Ended
	Apr. 21, 2016shares	Feb. 26, 2015shares	Mar. 31, 2017USD ($)shares	Mar. 31, 2016USD ($)shares	Dec. 31, 2014shares
Working Capital Surplus (Deficit) | $			$ 4,375,225	$ 187,156
Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $			$ (3,936,574)	$ 1,036,148
Stockholders' Equity, Reverse Stock Split			1-for-0.831105
Common Stock, Shares Authorized | shares			150,000,000	150,000,000	200,000,000
Retained Earnings (Accumulated Deficit) | $			$ (15,588,554)	$ (11,651,980)
Interactive Motion Technologies, Inc. [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares	23,650,000
Share Exchange Agreement [Member]
Stock Issued During Period, Shares, New Issues | shares		50,000,000
Debt Instrument, Convertible, Conversion Ratio		3.14
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage		100.00%

SIGNIFICANT ACCOUNTING POLICI36

SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Significant Accounting Policies [Line Items]
Standard and Extended Product Warranty Accrual	$ 64,957	$ 0
Product Warranty Expense	30,732	$ 0
Goodwill and Intangible Asset Impairment	$ 0
Computer And Electronics [Member]
Significant Accounting Policies [Line Items]
Percentage Of Depreciated Per Annum	50.00%
Furniture and Fixtures [Member]
Significant Accounting Policies [Line Items]
Percentage Of Depreciated Per Annum	20.00%
Demonstration Equipment [Member]
Significant Accounting Policies [Line Items]
Percentage Of Depreciated Per Annum	50.00%
Manufacturing Equipment [Member]
Significant Accounting Policies [Line Items]
Percentage Of Depreciated Per Annum	20.00%
Tool and Parts [Member]
Significant Accounting Policies [Line Items]
Percentage Of Depreciated Per Annum	20.00%

ACQUISITION (Details)

ACQUISITION (Details) - USD ($)		1 Months Ended
		Apr. 21, 2016	Mar. 31, 2017	Mar. 31, 2016
Business Acquisition [Line Items]
Fair value of 23,650,000 shares of common stock	[1]	$ 23,177,000
Fair value of vested stock options	[2]	2,582,890
Total Consideration Paid		25,759,890
Allocation of purchase price:
Cash and cash equivalents		266,635
Accounts receivable		6,490
Inventories		188,879
Prepaid expenses and other current assets		16,839
Equipment		59,749
Liabilities assumed:
Accounts payable		(241,299)
Accrued liabilities		(361,029)
Customer deposits		(86,487)
Demand notes payable		(324,894)
Promissory notes payable		(217,808)
Bionik advance	[3]	(1,436,164)
Net assets acquired		(2,129,089)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		1,306,031
Goodwill		22,308,275	$ 22,308,275	$ 0
Total Allocation of purchase price		25,759,890
Customer Relationships [Member]
Liabilities assumed:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		1,431,680
Non compete agreement [Member]
Liabilities assumed:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		61,366
Assembled Workforce [Member]
Liabilities assumed:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		275,720
Trademarks [Member]
Liabilities assumed:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		$ 2,505,907
[1]	The fair value of common shares was based on $0.98, which was the closing market price of the Company’s common stock on April 21, 2016.
[2]	The fair value of the vested stock options was determined using the Black Scholes option pricing model with the following key assumptions: a risk free rate of 1.59%, dividend and forfeiture rates of 0% and expected volatility of 114% which is consistent with the Company’s assumptions (Note 10).
[3]	Included in the net assets acquired was a loan issued to IMT in the amount of $300,000 under normal commercial terms. The loan carried an interest rate of 6% and were secured by all the assets of IMT subject to a $200,000 subordination to a third party financial services company, which was released in April 2016.

ACQUISITION (Details 1)

ACQUISITION (Details 1) - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Business Acquisition [Line Items]
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 5,580,704
Amortization of Intangible Assets	550,080	$ 0
Intangible Assets, Net (Excluding Goodwill)	$ 5,030,624	$ 0
Patents and exclusive License Agreement [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life	9 years 8 months 26 days
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 1,306,031
Amortization of Intangible Assets	126,375
Intangible Assets, Net (Excluding Goodwill)	$ 1,179,656
Trademark [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life	Indefinite
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 2,505,907
Amortization of Intangible Assets	0
Intangible Assets, Net (Excluding Goodwill)	$ 2,505,907
Customer relationships [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life	10 years
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 1,431,680
Amortization of Intangible Assets	134,931
Intangible Assets, Net (Excluding Goodwill)	$ 1,296,749
Non compete agreement [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life	2 years
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 61,366
Amortization of Intangible Assets	28,918
Intangible Assets, Net (Excluding Goodwill)	$ 32,448
Assembled Workforce [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life	1 year
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 275,720
Amortization of Intangible Assets	259,856
Intangible Assets, Net (Excluding Goodwill)	$ 15,864

ACQUISITION (Details Textual)

ACQUISITION (Details Textual)	1 Months Ended
	Apr. 21, 2016USD ($)$ / sharesshares
Business Acquisition [Line Items]
Fair Value Assumptions, Risk Free Interest Rate	1.59%
Fair Value Assumption Forfeited rate	0.00%
Fair Value Assumptions, Expected Volatility Rate	114.00%
Exercise Price 0.25 [Member]
Business Acquisition [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.25
Exercise Price 0.95 [Member]
Business Acquisition [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.95
Exercise Price 1.05 [Member]
Business Acquisition [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 1.05
Interactive Motion Technologies, Inc. [Member]
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	100.00%
Business Acquisition, Effective Date of Acquisition	Apr. 21, 2016
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	23,650,000
Business Acquisition, Number Of Option Acquired	3,895,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	3,000,000
Allocated Share-based Compensation Expense | $	$ 2,582,890
Share Price | $ / shares	$ 0.98
Loans and Leases Receivable, Related Parties | $	$ 300,000
Debt Instrument, Interest Rate, Stated Percentage	6.00%
Subordinated Debt | $	$ 200,000

PREPAID EXPENSES AND OTHER RE40

PREPAID EXPENSES AND OTHER RECEIVABLES (Details) - USD ($)		Mar. 31, 2017	Mar. 31, 2016
Prepaid Expense And Other Receivables [Line Items]
Prepaid expenses and other receivables		$ 68,484	$ 87,979
Prepaid insurance		136,896	107,259
Sales taxes receivable	[1]	22,667	36,495
Prepaid Expense and Other Assets		$ 228,047	$ 231,733
[1]	Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORY (Details)

INVENTORY (Details) - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Inventory [Line Items]
Raw Materials	$ 119,985	$ 0
Work in Progress	108,264	0
Inventory, Net	$ 228,249	$ 0

INVENTORY (Details Textual)

INVENTORY (Details Textual)	12 Months Ended
	Mar. 31, 2017USD ($)
Inventory Write-down	$ 43,009
InMotion Products [Member]
Inventory Write-down	$ 124,416

EQUIPMENT (Details)

EQUIPMENT (Details) - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Property, Plant and Equipment [Line Items]
Equipment, Cost	$ 595,102	$ 186,164
Accumulated Depreciation	367,681	109,414
Equipment, Net	227,421	76,750
Computers and electronics [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	250,538	152,246
Accumulated Depreciation	204,258	96,379
Equipment, Net	46,280	55,867
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	36,795	22,496
Accumulated Depreciation	26,096	10,118
Equipment, Net	10,699	12,378
Demonstration equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	184,586	0
Accumulated Depreciation	44,420	0
Equipment, Net	140,166	0
Manufacturing equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	88,742	0
Accumulated Depreciation	84,982	0
Equipment, Net	3,760	0
Tools and parts [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	11,422	11,422
Accumulated Depreciation	4,472	2,917
Equipment, Net	6,950	8,505
Assets under capital lease [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	23,019	0
Accumulated Depreciation	3,453	0
Equipment, Net	$ 19,566	$ 0

EQUIPMENT (Details Textual)

EQUIPMENT (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Property, Plant and Equipment [Line Items]
Depreciation	$ 79,868	$ 63,454

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) - Demand Notes payable [Member]	12 Months Ended
	Mar. 31, 2017USD ($)
Balance, March 31, 2016	$ 0
Acquisition of IMT (Note 3)	324,894
Accrued interest	5,706
Balance, March 31, 2017	$ 330,600

NOTES PAYABLE (Details 1)

NOTES PAYABLE (Details 1)	12 Months Ended
	Mar. 31, 2017USD ($)
Balance, March 31, 2016	$ 0
Balance, March 31, 2017	236,548
Promissory Note [Member]
Balance, March 31, 2016	0
Acquisition of IMT (Note 3)	217,808
Accrued interest	18,740
Balance, March 31, 2017	$ 236,548

NOTES PAYABLE (Details Textual)

NOTES PAYABLE (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2017	Jan. 15, 2017	Dec. 31, 2016	Apr. 21, 2016	Feb. 28, 2014
Convertible Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Debt Instrument, Face Amount	$ 2,000,000		$ 1,500,000
Debt Instrument, Maturity Date	Nov. 15, 2017
Interest Payable, Current	$ 17,488
Debt Instrument, Convertible, Terms of Conversion Feature	The convertible loans contain the following terms: convertible at the option of the holder at the price of the equity financing or payable on demand upon the completion of an equity financing greater than $5,000,000; automatically convertible at the price of the equity financing upon completion of an equity financing between $3,500,000 and $5,000,000
Convertible Loans Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	3,000,000
First Tranches [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 500,000
Second Tranches [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 500,000
Fourth Tranches [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 500,000
IMT Notes [Member]
Debt Instrument [Line Items]
Debt Instrument Demand Deferral, Minimum Capital Proceeds Required	$ 15,000,000
Notes Payable				$ 330,600
Debt Instrument, Interest Rate, Stated Percentage	3.50%
Interest Expense, Debt	$ 5,706
Promissory Note [Member]
Debt Instrument [Line Items]
Notes Payable					$ 200,000
Debt Instrument, Interest Rate, Stated Percentage					10.00%
Interest Expense, Debt	18,740
Director [Member] | IMT Notes [Member]
Debt Instrument [Line Items]
Notes Payable	$ 150,689

RELATED PARTY TRANSACTIONS AN48

RELATED PARTY TRANSACTIONS AND BALANCES (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Jun. 08, 2009
Related Party Transaction [Line Items]
Accrued interest receivable	$ 707
Royalty on Sales, Percentage			1.00%
Related Party Transaction, Rate	1.00%
Accounts Payable, Current	$ 784,726	$ 320,871
Repayments of Notes Payable	33,000
IMT Notes [Member]
Related Party Transaction [Line Items]
Debt Instrument Demand Deferral, Minimum Capital Proceeds Required	15,000,000
Director [Member]
Related Party Transaction [Line Items]
Accounts Payable, Current	120,000	0
Chief Operating Officer [Member]
Related Party Transaction [Line Items]
Due from Related Parties	18,731
Accounts Payable, Related Parties	12,607	8,812
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	4,135	2,694
Chief Technology Officer [Member]
Related Party Transaction [Line Items]
Due from Related Parties		41,445
Accounts Payable, Related Parties	0	3,284
Related Party Advances Receivable, Amount Forgave	22,182
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	$ 0	$ 116
Interactive Motion Technologies, Inc. [Member] | Director [Member]
Related Party Transaction [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	5,190,376
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	360,231

SHARE CAPITAL (Details)

SHARE CAPITAL (Details) - USD ($)		12 Months Ended
		Mar. 31, 2017	Mar. 31, 2016
Opening Balance		$ 263,906	$ (2,498,745)
Shares issued on acquisition (Note 3)		23,177,000
Shares issued for services			169,700
Options exercised		18,166
Warrants exercised		40,195
Cashless exercise of warrants (iv)		43,562	60,966
Closing Balance		$ 23,191,095	$ 263,906
Exchangable Shares [Member]
Opening Balance (in shares)		50,000,000	50,000,000
Opening Balance		$ 50,000	$ 50,000
Converted into common shares (in shares)		(2,090,664)	0
Converted into common shares		$ (2,090)	$ 0
Closing Balance (in shares)		47,909,336	50,000,000
Closing Balance		$ 47,910	$ 50,000
Common Shares [Member]
Opening Balance (in shares)		22,591,292	22,428,313
Opening Balance		$ 22,591	$ 22,428
Shares issued on acquisition (Note 3)		$ 23,650	$ 0
Shares issued on acquisition (Note 3) (in shares)		23,650,000	0
Shares issued to exchangeable shareholders (in shares)		2,090,664	0
Shares issued to exchangeable shareholders		$ 2,090	$ 0
Shares issued for services (in shares)	[1]	217,047	117,471
Shares issued for services	[1]	$ 217	$ 117
Options exercised (in shares)		110,096	0
Options exercised		$ 110	$ 0
Warrants exercised		$ 175	$ 0
Warrants exercised (in shares)		174,759	0
Cashless exercise of warrants (iv) (in shares)		51,249	45,508
Cashless exercise of warrants (iv)		$ 51	$ 46
Closing Balance (in shares)		48,885,107	22,591,292
Closing Balance		$ 48,884	$ 22,591
Common Shares And Exchangeable Shares [Member]
Opening Balance (in shares)		72,591,292
Opening Balance		$ 72,591
Closing Balance (in shares)		96,794,443	72,591,292
Closing Balance		$ 96,794	$ 72,591
[1]	During the year ended March 31, 2017, the Company issued 70,000 shares of common stock with a value of $59,500, 60,000 shares of common stock with a value of $36,000 and 87,047 shares of common stock with a value of $62,288 for services provided.

SHARE CAPITAL (Details Textual)

SHARE CAPITAL (Details Textual) - USD ($)	1 Months Ended			12 Months Ended
	Jun. 30, 2015	May 27, 2015	Apr. 21, 2015	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	Apr. 21, 2016
Stock Issued During Period, Value, Stock Options Exercised				$ 18,166
Stock Issued During Period, Value, Issued for Services					$ 169,700
Class of Warrant or Right, Outstanding				17,638,243
Fair Value Adjustment of Warrants				$ (4,176,390)	$ (7,742,555)	$ 6,036,659
Stock Issued During Period, Value, Warrants Exercised				$ 40,195
Interactive Motion Technologies, Inc. [Member]
Business Acquisition, Percentage of Voting Interests Acquired							100.00%
Issue for Services One [Member]
Stock Issued During Period, Shares, Issued for Services				70,000
Stock Issued During Period, Value, Issued for Services				$ 59,500
Issue for Services Two [Member]
Stock Issued During Period, Shares, Issued for Services				60,000
Stock Issued During Period, Value, Issued for Services				$ 36,000
Issue for Services Three [Member]
Stock Issued During Period, Shares, Issued for Services				87,047
Stock Issued During Period, Value, Issued for Services				$ 62,288
Service Agreements [Member]
Stock Issued During Period, Shares, Issued for Services					53,223
Investor Relation And Consultine Services [Member]
Stock Issued During Period, Shares, Issued for Services					134,248
Stock Issued During Period, Value, Issued for Services					$ 75,600
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.80
Stock Issued During Period, Shares, Upon Cashless Exercise Of Warrants				51,249
Number Of Warrants Exercised				262,045
Common Stock, Capital Shares Reserved for Future Issuance							23,650,000
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				110,096
Stock Issued During Period, Value, Stock Options Exercised				$ 110
Stock Issued During Period, Shares, Issued for Services					117,471
Stock Issued During Period, Value, Issued for Services					$ 117
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.80
Reclassification Of Warrants Liability To Additional Paid In Capital					$ 60,966
Stock Issued During Period, Shares, Upon Cashless Exercise Of Warrants				51,249	45,508
Number Of Warrants Exercised					148,787
Stock Issued During Period, Shares, Warrants Exercised				174,759
Stock Issued During Period, Value, Warrants Exercised				$ 175
Conversion of Stock, Shares Converted				2,090,664
Fourth Closing [Member]
Payments of Stock Issuance Costs			$ 338,960
Stock Units Issued During Period			3,115,000
Proceeds From Issuance of Stock Units			$ 2,492,000
Stock Units Description			Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years.
Warrants Exercisable Period			4 years
Class of Warrant or Right, Outstanding			311,500
Fair Value Adjustment of Warrants			$ 435,682
Warrants Exercisable Price Per Warrants			$ 0.80
Fifth Closing [Member]
Payments of Stock Issuance Costs		$ 147,566
Stock Units Issued During Period		1,418,750
Proceeds From Issuance of Stock Units		$ 1,135,000
Stock Units Description		Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years.
Warrants Exercisable Period		4 years
Class of Warrant or Right, Outstanding		141,875
Fair Value Adjustment of Warrants		$ 37,739
Warrants Exercisable Price Per Warrants		$ 0.80
Sixth Closing [Member]
Payments of Stock Issuance Costs	$ 211,656
Stock Units Issued During Period	2,035,000
Proceeds From Issuance of Stock Units	$ 1,628,000
Stock Units Description	Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years.
Warrants Exercisable Period	4 years
Class of Warrant or Right, Outstanding	203,500
Fair Value Adjustment of Warrants	$ 74,625
Warrants Exercisable Price Per Warrants	$ 0.80

STOCK OPTIONS (Details)

STOCK OPTIONS (Details) - Employee Stock Option [Member]	12 Months Ended
	Mar. 31, 2017USD ($)
February 17, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	4 years
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 136,613
July 1, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	3 years 4 months 6 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 1,259,487
June 20, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	5 years 3 months 25 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 118,957
April 11, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	3 years 1 month 20 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 230,930
November 24 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	6 years
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 694,384
December 14, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	6 years
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 1,260,437
April 21, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	8 years 6 months
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 2,582,890
April 26, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	8 years 6 months
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 213,750
August 8, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	6 years 3 months 18 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 652,068
February 6, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	6 years 10 months 10 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 245,200
February 13, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	6 years 10 months 10 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 148,750

STOCK OPTIONS (Details 1)

STOCK OPTIONS (Details 1) - Employee Stock Option [Member]	12 Months Ended
	Mar. 31, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Options, Outstanding, Beginning Balance (in shares) | shares	6,604,880
Number of Options, Issued (in shares) | shares	4,650,000
Number of Options, Exercised (in shares) | shares	(110,096)
Number of Options, Expired (in shares) | shares	(1,037,047)
Number of Options, Cancelled (in shares) | shares	(204,087)
Number of Options, Outstanding, Ending Balance (in shares) | shares	9,903,650
Weighted-Average Exercise Price, Outstanding, Beginning Balance (in dollars per share) | $ / shares	$ 0.57
Weighted-Average Exercise Price, Issued (in dollars per share) | $ / shares	0.54
Weighted-Average Exercise Price, Exercised (in dollars per share) | $ / shares	0.17
Weighted-Average Exercise Price, Expired (in dollars per share) | $ / shares	0.27
Weighted-Average Exercise Price, Cancelled (in dollars per share) | $ / shares	0.55
Weighted-Average Exercise Price, Outstanding, Ending Balance (in dollars per share) | $ / shares	$ 0.59

STOCK OPTIONS (Details 2)

STOCK OPTIONS (Details 2) - Employee Stock Option [Member] - $ / shares	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.59	$ 0.57
Number of Options	9,903,650	6,604,880
Number of Exercisable Options	6,362,689
Stock Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.165
Number of Options	264,230
Expiry Date	Apr. 1, 2021
Number of Exercisable Options	264,230
Stock Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.23
Number of Options	97,514
Expiry Date	Jun. 20, 2021
Number of Exercisable Options	97,514
Stock Option Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.23
Number of Options	1,981,728
Expiry Date	Jul. 1, 2021
Number of Exercisable Options	1,981,728
Stock Option Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.23
Number of Options	204,471
Expiry Date	Feb. 17, 2022
Number of Exercisable Options	204,471
Stock Option Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1.22
Number of Options	400,000
Expiry Date	Nov. 24, 2022
Number of Exercisable Options	133,333
Stock Option Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1
Number of Options	2,400,000
Expiry Date	Dec. 14, 2022
Number of Exercisable Options	809,994
Stock Option Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.95
Number of Options	111,937
Expiry Date	Mar. 28, 2023
Number of Exercisable Options	111,937
Stock Option Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1.05
Number of Options	433,027
Expiry Date	Mar. 28, 2023
Number of Exercisable Options	433,027
Stock Option Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1
Number of Options	250,000
Expiry Date	Apr. 26, 2023
Number of Exercisable Options	0
Stock Option Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1
Number of Options	750,000
Expiry Date	Aug. 8, 2023
Number of Exercisable Options	0
Stock Option Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.70
Number of Options	400,000
Expiry Date	Feb. 6, 2024
Number of Exercisable Options	0
Stock Option Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.68
Number of Options	250,000
Expiry Date	Feb. 13, 2024
Number of Exercisable Options	0
Stock Option Thirteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.95
Number of Options	31,620
Expiry Date	Mar. 3, 2024
Number of Exercisable Options	31,620
Stock Option Fourteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1.05
Number of Options	122,324
Expiry Date	Mar. 3, 2024
Number of Exercisable Options	122,324
Stock Option Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.95
Number of Options	15,810
Expiry Date	Mar. 14, 2024
Number of Exercisable Options	15,810
Stock Option Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1.05
Number of Options	61,162
Expiry Date	Mar. 14, 2024
Number of Exercisable Options	61,162
Stock Option Seventeen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.95
Number of Options	82,213
Expiry Date	Sep. 30, 2024
Number of Exercisable Options	82,213
Stock Option Eighteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1.05
Number of Options	318,042
Expiry Date	Sep. 30, 2024
Number of Exercisable Options	318,042
Stock Option Nineteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.95
Number of Options	7,431
Expiry Date	Jun. 2, 2025
Number of Exercisable Options	7,431
Stock Option Twenty [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1.05
Number of Options	28,747
Expiry Date	Jun. 2, 2025
Number of Exercisable Options	28,747
Stock Option Twenty One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.25
Number of Options	906,077
Expiry Date	Jul. 28, 2025
Number of Exercisable Options	906,077
Stock Option Twenty Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.95
Number of Options	671,859
Expiry Date	Jul. 29, 2025
Number of Exercisable Options	671,859
Stock Option Twenty Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.25
Number of Options	66,298
Expiry Date	Dec. 30, 2025
Number of Exercisable Options	53,909
Stock Option Twenty Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.95
Number of Options	49,160
Expiry Date	Dec. 30, 2025
Number of Exercisable Options	27,261

STOCK OPTIONS (Details Textual)

STOCK OPTIONS (Details Textual) - USD ($)

Feb. 06, 2017

Oct. 08, 2016

Aug. 08, 2016

Dec. 14, 2015

Feb. 13, 2017

Apr. 26, 2016

Apr. 21, 2016

Nov. 24, 2015

Feb. 26, 2015

Feb. 17, 2015

Dec. 31, 2014

Mar. 31, 2017

Mar. 31, 2016

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term

5 years 1 month 13 days

5 years 10 months 20 days

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

6 years 7 days

5 years 3 months 4 days

Exercise Price Range One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

1,000,000

Exercise Price Range Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

1,000,000

Exercise Price Range Three [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

1,000,000

Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated Share-based Compensation Expense

$ 844,162

$ 1,495,837

Adjustments to Additional Paid in Capital, Share-based Compensation and Exercise of Stock Options

$ 59,479

April issuance [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

531,606

Share Based Compensation Arrangement By Share Based Payment Award Options Re-measured Fair value

$ 230,930

June issuance [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

264,230

Allocated Share-based Compensation Expense

$ 118,957

Employees and Consultant [Member] | Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

125,824

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

62,912

Employees and Consultant [Member] | April issuance [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

657,430

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.165

Employees and Consultant [Member] | June issuance [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

264,230

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.23

Management [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

2,972,592

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.23

Share Based Compensation Arrangement By Share Based Payment Award Options Issued Weighted Average Remaining Contractual Term1

7 years

Fair Value Of Options

$ 1,259,487

Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period

990,864

Director and Employees and Consultant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.23

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

110,100

Allocated Share-based Compensation Expense

$ 407,208

Fair Value Of Options

$ 136,613

Employees of Bionik Inc [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 1

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

3,895,000

Allocated Share-based Compensation Expense

66,104

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

250,000

3,000,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value

$ 213,750

$ 2,582,890

Employees of Bionik Inc [Member] | Exercise Price Range One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

0.25

Employees of Bionik Inc [Member] | Exercise Price Range Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

0.95

Employees of Bionik Inc [Member] | Exercise Price Range Three [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 1.05

Employees of Bionik Inc [Member] | Unvested option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated Share-based Compensation Expense

$ 102,989

Employees [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

650,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

250,000

Allocated Share-based Compensation Expense

$ 142,438

$ 62,317

Fair Value Of Options

$ 694,384

Employee One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 1

Allocated Share-based Compensation Expense

$ 140,230

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

750,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value

$ 652,068

Director and Employees and Consultant One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

2,495,000

314,560

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

40,000

25,000

Allocated Share-based Compensation Expense

$ 26,164

Fair Value Of Options

$ 1,260,437

Employee Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.70

Allocated Share-based Compensation Expense

12,163

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

400,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value

$ 245,200

Consultant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.68

Allocated Share-based Compensation Expense

$ 6,345

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

250,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value

$ 148,750

WARRANTS (Details)

WARRANTS (Details) - $ / shares	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Number of Warrants, Outstanding and exercisable, Beginning balance	17,900,288	10,823,450
Number of Warrants, Issued		7,225,625
Number of Warrants, Issued, Exercised	(262,045)	(148,787)
Number of Warrants, Outstanding and exercisable, Ending balance	17,638,243	17,900,288
Weighted-Average Exercise Price, Outstanding and exercisable, Beginning balance	$ 1.35	$ 1.35
Weighted-Average Exercise Price, Issued		1.35
Weighted-Average Exercise Price, Exercised	(0.80)	(0.80)
Weighted-Average Exercise Price, Outstanding and exercisable, Ending balance	$ 1.35	$ 1.35

WARRANTS (Details 1)

WARRANTS (Details 1) - $ / shares	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Warrants	17,638,243
Warrant One [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.40
Class of Warrant or Right, Number of Warrants	7,735,750	7,735,750
Class Of Warrant Or Right Expiry Date	Feb. 26, 2019
Warrant Three [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.40
Class of Warrant or Right, Number of Warrants	1,212,500	1,212,500
Class Of Warrant Or Right Expiry Date	Mar. 27, 2019
Warrant Five [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.40
Class of Warrant or Right, Number of Warrants	891,250	891,250
Class Of Warrant Or Right Expiry Date	Mar. 31, 2019
Warrant Seven [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.40
Class of Warrant or Right, Number of Warrants	3,115,000	3,115,000
Class Of Warrant Or Right Expiry Date	Apr. 21, 2019
Warrant Nine [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.40
Class of Warrant or Right, Number of Warrants	1,418,750	1,418,750
Class Of Warrant Or Right Expiry Date	May 27, 2019
Warrant Eleven [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.40
Class of Warrant or Right, Number of Warrants	2,035,000	2,035,000
Class Of Warrant Or Right Expiry Date	Jun. 30, 2019
Warrant Thirteen [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.80
Class of Warrant or Right, Number of Warrants	1,229,993
Class Of Warrant Or Right Expiry Date	Feb. 26, 2019

WARRANTS (Details 2)

WARRANTS (Details 2) - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Derivative Liability, Fair Value, Gross Liability	$ 5,135,990	$ 8,382,648
Fair value of warrants exercised		(60,966)
Change in fair value of warrant derivative liability	$ (4,176,390)	(7,742,555)	$ 6,036,659
Class of Warrant or Right, Outstanding	17,638,243
Derivative Liability, Fair Value, Gross Liability	$ 959,600	$ 5,135,990	$ 8,382,648
Warrants Issued In February 26, 2015 Financing [Member]
Class of Warrant or Right, Outstanding		8,509,325
Derivative Liability, Fair Value, Gross Liability		$ 550,374
Class of Warrant or Right, Outstanding			8,509,325
Derivative Liability, Fair Value, Gross Liability			$ 550,374
Warrants Issued In March 27, 2015 Financing [Member]
Class of Warrant or Right, Outstanding		1,333,750
Derivative Liability, Fair Value, Gross Liability		$ 1,036,325
Class of Warrant or Right, Outstanding			1,333,750
Derivative Liability, Fair Value, Gross Liability			$ 1,036,325
Warrants Issued In March 31, 2015 Financing [Member]
Class of Warrant or Right, Outstanding		980,375
Derivative Liability, Fair Value, Gross Liability		$ 759,290
Class of Warrant or Right, Outstanding			980,375
Derivative Liability, Fair Value, Gross Liability			$ 759,290
Warrants Issued In April 21, 2015 Financing [Member]
Class of Warrant or Right, Outstanding		3,426,500
Derivative Liability, Fair Value, Gross Liability		$ 2,588,722
Class of Warrant or Right, Outstanding			3,426,500
Derivative Liability, Fair Value, Gross Liability			$ 2,588,722
Warrants Issued In May 27, 2015 Financing [Member]
Class of Warrant or Right, Outstanding		1,560,625
Derivative Liability, Fair Value, Gross Liability		$ 1,025,173
Class of Warrant or Right, Outstanding			1,560,625
Derivative Liability, Fair Value, Gross Liability			$ 1,025,173
Warrants Issued In June 30, 2015 Financing [Member]
Class of Warrant or Right, Outstanding		2,238,500
Derivative Liability, Fair Value, Gross Liability		$ 1,490,969
Class of Warrant or Right, Outstanding			2,238,500
Derivative Liability, Fair Value, Gross Liability			$ 1,490,969

WARRANTS (Details 3)

WARRANTS (Details 3) - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Number of Warrants	17,638,243
Warrant One [Member]
Number of Warrants	7,735,750	7,735,750
Expected life in years		4 years
Exercise Price		$ 1.4
Risk free rate		0.44%
Dividend rate		0.00%
Expected volatility		51.83%
Fair value		$ 464,784
Warrant Two [Member]
Number of Warrants		773,575
Expected life in years		4 years
Exercise Price		$ 0.8
Risk free rate		0.44%
Dividend rate		0.00%
Expected volatility		51.83%
Fair value		$ 85,590
Warrant Three [Member]
Number of Warrants	1,212,500	1,212,500
Expected life in years		3 years 11 months 1 day
Exercise Price		$ 1.4
Risk free rate		0.43%
Dividend rate		0.00%
Expected volatility		52.37%
Fair value		$ 950,913
Warrant Four [Member]
Number of Warrants		121,250
Expected life in years		3 years 11 months 1 day
Exercise Price		$ 0.8
Risk free rate		0.43%
Dividend rate		0.00%
Expected volatility		52.37%
Fair value		$ 85,412
Warrant Five [Member]
Number of Warrants	891,250	891,250
Expected life in years		3 years 10 months 28 days
Exercise Price		$ 1.4
Risk free rate		0.41%
Dividend rate		0.00%
Expected volatility		52.45%
Fair value		$ 696,582
Warrant Six [Member]
Number of Warrants		89,125
Expected life in years		3 years 10 months 28 days
Exercise Price		$ 0.8
Risk free rate		0.41%
Dividend rate		0.00%
Expected volatility		52.45%
Fair value		$ 62,708
Warrant Seven [Member]
Number of Warrants	3,115,000	3,115,000
Expected life in years		3 years 10 months 6 days
Exercise Price		$ 1.4
Risk free rate		0.68%
Dividend rate		0.00%
Expected volatility		51.54%
Fair value		$ 2,371,956
Warrant Eight [Member]
Number of Warrants		311,500
Expected life in years		3 years 10 months 6 days
Exercise Price		$ 0.8
Risk free rate		0.68%
Dividend rate		0.00%
Expected volatility		51.54%
Fair value		$ 216,766
Warrant Nine [Member]
Number of Warrants	1,418,750	1,418,750
Expected life in years		3 years 9 months 4 days
Exercise Price		$ 1.4
Risk free rate		0.46%
Dividend rate		0.00%
Expected volatility		51.74%
Fair value		$ 933,065
Warrant Ten [Member]
Number of Warrants		141,875
Expected life in years		3 years 9 months 4 days
Exercise Price		$ 0.8
Risk free rate		0.46%
Dividend rate		0.00%
Expected volatility		51.74%
Fair value		$ 92,108
Warrant Eleven [Member]
Number of Warrants	2,035,000	2,035,000
Expected life in years		3 years 7 months 28 days
Exercise Price		$ 1.4
Risk free rate		0.37%
Dividend rate		0.00%
Expected volatility		52.94%
Fair value		$ 1,356,512
Warrant Twelve [Member]
Number of Warrants		203,500
Expected life in years		3 years 7 months 28 days
Exercise Price		$ 0.8
Risk free rate		0.37%
Dividend rate		0.00%
Expected volatility		52.94%
Fair value		$ 134,457
Classes of Warrants 1 [Member]
Number of Warrants	16,408,250	16,408,250
Expected life in years	1 year 10 months 28 days	2 years 10 months 28 days
Exercise Price	$ 1.4	$ 1.4
Risk free rate	0.65%	0.21%
Dividend rate	0.00%	0.00%
Expected volatility	53.58%	62.96%
Fair value	$ 849,713	$ 4,585,539
Classes Of Warrants 2 [Member]
Number of Warrants	1,229,993	1,492,038
Expected life in years	1 year 10 months 28 days	2 years 10 months 28 days
Exercise Price	$ 0.8	$ 0.8
Risk free rate	0.65%	0.21%
Dividend rate	0.00%	0.00%
Expected volatility	53.58%	62.96%
Fair value	$ 109,887	$ 550,451

WARRANTS (Details Textual)

WARRANTS (Details Textual) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2014	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Class of Warrant or Right [Line Items]
Fair Value Adjustment of Warrants		$ (4,176,390)	$ (7,742,555)	$ 6,036,659
Derivative, Gain on Derivative		$ 4,176,230	$ 8,290,556
Warrant Redemption Terms		The Company has the option to redeem the warrants for $0.001 per warrant if the daily volume weighted-average price of the common shares is 200% or more of the exercise price for twenty consecutive trading days provided there is an effective registration statement covering the shares of common stock available throughout the thirty day period after the redemption date. The warrant holders then have thirty days to exercise the warrants or receive the redemption amount.
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumption, Holding Cost Percentage		2.25%
Daily Volume Weighted Average Share Price Minimum Threshold Percentage		200.00%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms		1 year 9 months 7 days	2 years 9 months 7 days
Number Of Warrants Exercised		262,045	148,787
Stock Issued During Period, Value, Warrants Exercised		$ 40,195
Common Shares [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, Upon Cashless Exercise Of Warrants		51,249	45,508
Stock Issued During Period, Shares, Warrants Exercised		174,759
Accrued Liabilities [Member]
Class of Warrant or Right [Line Items]
Repayments of Debt	$ 12,138
Warrant [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations		174,763
Investor [Member]
Class of Warrant or Right [Line Items]
Repayments of Debt	$ 180,940
Debt Conversion, Converted Instrument, Warrants or Options Issued	349,522
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.23

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Components of net loss before income taxes consists of the following:
U.S.	$ (1,923,556)	$ 4,706,413
Canada	(2,013,018)	(3,670,265)
Net (loss) income for the year before recovery of income taxes	$ (3,936,574)	$ 1,036,148
Statutory rate	35.00%	35.00%
Expected income tax (recovery) expense	$ (1,377,801)	$ 362,652
Tax rate changes and other basis adjustments	59,484	195,108
Change in fair value of derivative liability	(1,461,681)	(2,709,894)
Stock-based compensation	350,683	512,693
Non-deductible expenses	(132,076)	(12,073)
Net DTA acquired	(546,122)	0
Change in valuation allowance	3,107,513	1,651,514
Recovery of income taxes	$ 0	$ 0

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Equipment	$ 73,520	$ 52,331
Share issue costs	1,456	3,586
SR&ED pool	464,746	400,557
Other	629,266	215,202
Non-capital losses - Canada	2,067,203	1,587,439
Net operating losses - U.S.	4,534,710	589,491
Valuation allowance	(5,956,118)	(2,848,606)
Deferred Tax Liabilities, Net, Total	1,814,783	0
Intangibles and other	(1,814,783)	0
Deferred Tax Assets, Net	$ 0	$ 0

INCOME TAXES (Details 2)

INCOME TAXES (Details 2)	12 Months Ended
	Mar. 31, 2017
Domestic Tax Authority [Member] | United States - Federal [Member]
Income Tax Examination Open Tax Years	2013 – present
Domestic Tax Authority [Member] | United States - State [Member]
Income Tax Examination Open Tax Years	2013 – present
Foreign Tax Authority [Member] | Canada - Federal [Member]
Income Tax Examination Open Tax Years	2012 – present
Foreign Tax Authority [Member] | Canada - Provincial [Member]
Income Tax Examination Open Tax Years	2012 – present

INCOME TAXES (Details Textual)

INCOME TAXES (Details Textual)	Mar. 31, 2017USD ($)
Tax Credit Carryforward, Amount	$ 3,513,000
Canada [Member]
Tax Credit Carryforward, Amount	7,800,000
UNITED STATES
Tax Credit Carryforward, Amount	$ 8,620,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Feb. 25, 2015	Mar. 31, 2017	Mar. 31, 2016
Stock Issued During Period, Value, Issued for Services			$ 169,700
Share-based Compensation		$ 1,001,950	$ 1,495,837
Exchangable Shares [Member]
Stock Issued During Period, Shares, Issued for Services	262,904
Stock Transferred To Lenders	314,560
Stock Reimbursed To Officers	320,000
Stock Issued During Period, Value, Issued for Services	$ 241,185
Share-based Compensation	$ 210,323

RISK MANAGEMENT (Details Textua

RISK MANAGEMENT (Details Textual)	Mar. 31, 2017CAD
Canada [Member] | Maximum [Member]
Concentration Risk [Line Items]
Cash, FDIC Insured Amount	CAD 100,000

(LOSS) PER SHARE (Details)

(LOSS) PER SHARE (Details) - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Numerator
Net loss		$ (1,036,148)
Change in fair value of warrant derivative liability	$ (4,176,390)	(7,742,555)	$ 6,036,659
Net (loss) used in computation of diluted EPS		$ (6,706,407)
Denominator
Basic weighted average number of shares outstanding	91,784,976	71,554,822
Warrants		8,429,435
Diluted weighted average number of shares outstanding	91,784,976	79,984,257
Diluted loss per share	$ (0.04)	$ (0.08)

SUBSEQUENT EVENTS (Details Text

SUBSEQUENT EVENTS (Details Textual) - USD ($)	1 Months Ended
	Jun. 27, 2017	May 23, 2017	May 23, 2016	May 25, 2017	Mar. 31, 2017
Subsequent Event [Line Items]
Class of Warrant or Right, Outstanding					17,638,243
Subsequent Event [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.25
Class of Warrant or Right, Outstanding	12,700,000
Payment For Placement Agent Fees	$ 125,000
Warrant Holders Exercised Shares	5,000,000
Warrant Holders Exercised Amount	$ 1,250,000
Subsequent Event [Member] | Corporate Joint Venture [Member]
Subsequent Event [Line Items]
Capital		$ 1,450,000
Subsequent Event [Member] | Exercise Price 1.40 Warrant [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				1.40
Subsequent Event [Member] | Exercise Price 0.80 Warrant [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.80
Ginger Capital Investment Holding Ltd [Member]
Subsequent Event [Line Items]
Payments to Acquire Interest in Joint Venture			$ 500,000
Ginger Capital Investment Holding Ltd [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Profit distribution Description		Any profit distribution will be 75% in favor of Ginger Capital and 25% in favor of the Company
Warrant Fixed Interest Rate		8.00%
Description for New Round Stock		(i) $0.50 per New Round Stock and (ii) the quotient obtained by dividing (x) the Outstanding Balance on the conversion date multiplied by 1.10 by (y) the actual price per New Round Stock in the Qualified Financing. Upon the Maturity Date, Ginger Capital shall further be issued the Warrant, exercisable into a number of shares of the Companys common stock equal to (i) in the case of the conversion of the Note, 25% of the number of shares issued upon conversion and (ii) in the case of the repayment of the Note in cash, the number of shares of Common Stock equal to the quotient obtained by dividing the Outstanding Balance by 4. The exercise price per share is $0.60.
Proceeds from Divestiture of Interest in Joint Venture		$ 3,000,000